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1.1 Introduction 
At the beginning of this century, it was demonstrated that growth is regulated by a 
pituitary factor, currently called growth hormone (1). In 1921 for the first time growth 
promoting effects of crude anterior pituitary extracts were demonstrated in 
hypophysectomized and intact laboratory animals (2). Initially, growth hormone (GH) 
was prepared from animal sources, but it became evident that non primate GH was 
inactive in man (3). Early reports on the effects of human growth hormone administration 
date from the 1950s (3-10). It must be emphasized that the supply of human pituitary 
GH for clinical use was dependent on the availability of post-mortem pituitaries, the 
collection of which required cooperation of a large number of pathologists. Thus, save 
for short-term metabolic studies, between 1960 and 1985 the major use of pituitary GH 
was for the treatment of GH deficient (GHO) children. In 1964 the results were published 
of long-term human growth hormone administration for up to 2.5 years in 35 patients 
with short stature (11). The introduction of a radioimmunoassay (RIA) for the 
measurement of plasma growth hormone concentrations enabled quantitative 
assessment of GH secretion and restriction of GH therapy to (GHO) patients (12). Since 
the growth response was more pronounced in hypopituitary patients and supplies were 
scarce, it was decided that human GH therapy should be restricted to children with 
"classic" GHO. Between the late 1950s and 1985 thousands of children were treated 
with GH extracted from human pituitary glands. 
In 1979 biosynthetic or recombinant human growth hormone (rhGH) was manufactured 
(13). In 1982 it was shown to be effective in man (14). Introduction of biosynthetic GH 
preceded the reports of several GHO patients who had contracted Creutzfeld-Jakob 
disease (15). Since it was suspected that the patients had been infected by human 
pituitary-derived GH the clinical use of pituitary GH was suspended (16-24). After 1985 
there have been 51 cases of Creutzfeld-Jakob disease in patients previously treated 
with pituitary-derived human GH (25,26). As the incubation period of this disease can be 
as long as 35 years, new cases can be expected until the year 2020 (26). 
Early short-term studies had been designed not only to document the efficacy of growth 
promotion, but also to assess the metabolic effects of GH therapy (8,10). Reports on the 
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physiological consequences of GHD in adults appeared since the 1960s (27). 
Systematic investigation of the characteristics of GHD in adults, however, began in the 
late 1980s with the introduction of rhGH and led to the description of the growth 
hormone deficiency syndrome (28). 
The wide availability of rhGH has greatly expanded the therapeutic spectrum for its use. 
Also it stimulated the study of GH physiology and its actions. 
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1.2 The physiology of growth hormone secretion, modes of action and 
the assessment of growth hormone deficiency 
Growth hormone (GH) is a single chain polypeptide of 191 amino acids, which is 
produced by the somatotropic cells of the anterior pituitary gland. Most of the naturally 
occurring GH is present in the 22 kD form (90%). About 10% is present in the 20 kD 
form. In addition to its role in promoting linear growth in children (29), GH is an important 
anabolic hormone with stimulatory effects on protein synthesis and on lipolysis 
(10,30-33). 
Pituitary GH secretion is primarily regulated by the interaction of two hypothalamic 
peptides, GH-reteasing hormone (GHRH) and somatostatin (somatotropin-retease 
inhibitory factor), which are secreted into sinusoidal capillaries of the median eminence 
and reach the anterior pituitary gland via its portal veins. Naturally occurring 
hypothalamic GHRH binds to specific cell surface receptors on pituitary somatotropes 
and stimulates GH synthesis and release (34). The main physiologic action of 
somatostatin is to inhibit the synthesis and release of GH (35). GH is secreted in a 
pulsatile pattern (36). Human studies in which GH has been measured at frequent 
intervals have shown that most GH secretion occurs at night. Spontaneous GH release 
is primarily under tonic inhibitory control by somatostatin and increases when 
hypothalamic somatostatin secretion decreases (36,37). GH stimulates the liver and 
other peripheral tissues to produce insulin-like growth factor-I (IGF-I) (38-40), which in 
turn exerts a negative feedback in the hypothalamus and pituitary to suppress further 
GH release (41). Most metabolic effects of GH are mediated via IGF-I. 
GH secretion increases transiently after exercise (42). In addition age, obesity, 
depression, and hyperglycemia reduce (stimulated) secretion of GH (43-47). However, 
depressed patients have elevated GH levels during daytime, but not during sleep (46). 
Basal GH levels in type I diabetes mellitus are increased in poorly controlled patients 
(47). 
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Human GH circulates in the blood partially bound to GH-binding protein (GHBP), which 
is synthesized in the liver (48,49). GH binds to transmembrane glycoprotein receptors of 
which the extramembraneous portion is identical to GHBP (50,51). 
GH action 
Direct effects of GH comprise the stimulation of longitudinal growth through direct effects 
on chondrocytes and osteoblasts (29,52,53), effects on carbohydrate and' fat 
metabolism (54). GH decreases body fat by increasing the hydrolysis of triglycerides, 
releasing free fatty acids (FFA) and glycerol while decreasing FFA re-esterification 
(55,56). Also GH promotes a positive nitrogen balance (32,33,57-63). The mechanisms 
by which GH induces sodium retention are complex. Evidence exists for both a direct 
renal effect of GH and an indirect effect mediated by the renin-angiotensin system (64). 
IGF-I 
Indirect effects of GH are mediated mainly via IGF-I, most of which is of hepatic origin 
(38-40). Local tissue production of IGF-I, however, forms a large contribution to 
circulating IGF-Ilevels (65). Therefore IGF-I may act as a paracrine/autocrine factor, as 
well as as a hormone. IGF-I activates a specific cell-surface receptor which is 
structurally is very similar to the insulin receptor. 
GH stimulates bone growth directly by stimulating the differentiation of epiphyseal 
growth plate precursor cells and indirectly by increasing the responsiveness to IGF-I 
and enhancing the local prodUction of IGF-I (29,52). Thus, serum IGF-I levels do not 
completely account for, and may not be an accurate index of IGF-I tissue effects. 
Circulating IGF-I levels are low in patients with GH-deficiency and increase during GH 
replacement therapy, reflecting the decrease or absence of spontaneous GH secretion 
(66,67). 
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IGF-binding proteins (IGFBPs) 
IGF-I is present in blood and tissue both free and bound to at least six IGF-binding 
proteins (IGFBPs) of which IGFBP-3 (also previously known as GH-dependent BP) is 
the predominant circulating binding protein in postnatal life and accounts for nearly 95% 
of the total IGFBP activity (68-70). The physiological role of the IGFBPs is uncertain 
They may act as a reservoir for IGF-I, since they bind with 70-95% of the circulating 
IGF-I in plasma (68,71,72). IGFBP-3 levels are correlated with GH secretion; in GHD 
there are decreased levels, which normalize during GH replacement therapy (68,69,73). 
In acromegaly there are increased levels of IGFBP-3, which decrease after treatment 
with somatostatin (68). 
Although IGFBP-1 levels have been reported to be elevated in GHD and depressed in 
acromegaly it appears that IGFBP-1 production is GH-independent and is more related 
to plasma insulin levels (74,75). IGFBP-1 may act as an inhibitor of IGF-I action. 
Assessment of GH deficiency 
So far little attention has been paid to diagnostic criteria of GHD in adults (GHDA). In 
children before the advent of radioimmunoassays, prerequisites for the diagnosis were 
retarded longitudinal growth and evidence of pituitary disease involving one or more 
additional pituitary hormones. After the introduction of the RIA method it was 
recommended that the diagnosis of GHD should be based on an absent or subnormal 
GH peak after stimulation. 
In adults GHD has been defined to be present when maximum peak levels of GH after 
provocative testing do not exceed 0.5 to 5 !lg/L depending on the cut-off values that 
have been (arbitrarily) chosen (66,67,76). When comparing stimulated GH release, 
spontaneous GH secretion, IGF-I, and IGFBP-3 in adults with suspected GHD, insulin-
induced hypoglycemia is the only test which separates patients with organic 
hypothalamic/pituitary disease from their matched normal controls (77). However, this 
test is potentially dangerous and uncomfortable, which limits its use to experienced 
endocrine units under adequate supervision (78,79). 
The acute GH response to an arginine infusion has been found comparable in young 
and old men and similar degree of GH stimUlation was reported as that achieved by an 
15 
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insulin induced hypoglycemia (80-82). Arginine induced GH release is mainly induced 
by a decrease in somatostatinergic tone, while GH responses to hypoglycemia are 
probably mediated by both an increase in hypothalamic GHRH and an inhibition of 
somatostatin release (83). 
The use of GHRH to stimulate GH secretion is accurate, more easy to perform and has 
less side-effects (84-87). 
Since IGF-I is GH-dependent it might also be used for screening patients with 
suspected GHD (88,89). It is important to realize, that IGF-I is also dependent on the 
nutritional status of the patient (90,91). 
Also IGFBP-3 levels are regulated by GH. In children it was found a good (73) as well 
as a poor (92) indicator of the GH secretory status. In conclusion GHD is considered to 
be present, when there is a history of pituitary disease, in combination with a lowered 
GH response to a provocation test. Solely for screening purposes the assessment of 
IGF-I or IGFBP levels might be performed, but there seems to exist a considerable 
overlap between GHD individuals and their age- and sex-matched controls (77). 
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1.3 Nitrogen metabolism 
Following infection, injury or surgical trauma, an obligatory loss of protein emerges. This 
is caused by the mobilization of amino acids from skeletal muscle, the major site of body 
protein. Whole body nitrogen balance becomes negative, as the amino acids are 
transported to the visceral organs, 
Table 1. Estimates of cumulative nitrogen where they serve as precursors for 
loss following catabolic illness acute phase proteins and glucose. 
(first ten days, ad libitum feeding) The nitrogen released from the 
Precipitating factor Cumulative nitrogen 
loss (g) 
Major burn 170 
Multiple injury 150 
Peritonitis 136 
Single fracture 115 
Major operation 50 
Minor operation 24 
Pneumonia 59 
Adapted from ref. 93 
amino acids forms urea, which is 
excreted in the urine. The amount of 
nitrogen loss generally is proportional 
to the severity of the illness (Table 1). 
The protein losses are minimal and 
well tolerated, if the patient is 
healthy, body composition is normal, 
and the clinical course is 
uncomplicated. Prolonged protein 
losses lead to protein malnutrition. 
These patients will often develop 
delayed wound healing, are more 
sensitive to infections, and eventually 
their recovery may be jeopardized. 
Administration of adequate or even supraphysiologic quantities of protein and calories 
decrease, but do not abolish the negative nitrogen balance and muscle breakdown (94). 
Studies of protein turnover demonstrate that feeding of the critically ill does not alter the 
accelerated breakdown, but it increases protein synthesis resulting in a reduction of net 
protein loss (95). Since there is a strong association between a poor nutritional status 
and a poor outcome in the surgical patient, it is important to maximize efforts to improve 
nutritional efficiency (96). 
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Growth hormone has long been known for its anabolic effects (6). These include a 
positive nitrogen, phosphorus, potassium and magnesium balance. The ratio of 
potassiumlproteinsparing is 3:1, which is comparable to that found in muscle (58). A 
reduction in blood urea concentration is an easily detectable biochemical change 
associated with the anabolic actions of GH (97). Since GH also liberates metabolic fuels 
by lipolysis it is the drug of choice as anabolic agent (50). The role of GH in nitrogen 
metabolism will be further discussed in chapter 1.6. 
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1.4. Body composition assessment 
Before discussing body composition in GHD adults some general principles and 
methods of body composition assessment will be reviewed more extensively with 
special emphasis on the ones used in the studies that are presented in this thesis. 
Indirect methods of body composition assessment are based on models in which the 
body is divided in several (two or four) distinct compartments or components. These 
methods involve measurements of a physical property of such a compartment, from 
which body composition subsequently is calculated. Most methods use the two 
compartment model in which the body is divided in fat mass (FM) and fat free mass 
(FFM) or lean body mass (LBM). The terms LBM and FFM are not equivalent, 
representing the nonadipose tissue mass and the nonlipid mass, respectively. Adipose 
tissue contains water and protein. However, LBM and FFM become functionally 
equivalent when estimated indirectly from total body water (TBW) measurements, 
because the procedure assumes that adipose tissue is anhydrous. This results in an 
overestimation of LBM (by approximately two percent), which differs from FFM by 
protein alone (98,99). Assessment of LBM is important because it consists for fifty 
percent offat free muscle (100). 
The components of the body have their specific physical properties. The FM is 
anhydrous, potassium free and has a density of 0.9 glml at 37 ~C, while the FFM is 
considered to have a water content of 73% (101), a potassium content of approximately 
66 mmol/kg and a relative constant density of 1.1 g/ml at 37 'C. The calculation of the 
compartments can be accomplished by using either a statistically derived equation (e.g. 
bioelectrical impedance analysis (BIA) for calculating TBW) or a model equation (e.g. 
calculating an unknown component from a property derived component, FFM = TBWI 
0.73). 
Methods that use the two compartment model are assessment of TBW, total body 
potassium, urinary creatinine excretion, under water weighing (UWW) and 
anthropometry. 
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In Ihe four compartment model Ihe body is divided in water, protein, bone mineral and 
fal. Over the past several years, important refined or new techniques of body 
composition assessment have been inlroduced, which opened the possibility of 
eslimaling almost all the componenls of body composilion. These include computerized 
tomography (CT), in vivo neulron aclivalion analysis, dual-photon absorpliometry (DPA), 
dual energy X-ray absorpliometry (DXA) and magnetic resonance imaging (MRI). 
Anthropometry 
Anlhropometric measurements of the human body are body heighl, weighl, skinfold 
thickness, arm circumference, waist-hip ralio. Through ralher empirically-derived 
equalions body density, body fal and fat free mass can be calculated from a 
combinalion of these measurements. The major advantages of anthropomelry over 
other melhods of estimaling body composilion are that il is inexpensive and easy to 
perform. 
Generalized skinfold equations that are mostly used were developed by Durnin and 
Womersley (102). Skinfolds are measured wilh calipers according standardized 
guidelines. The variables age, sex and sum of four skinfolds are used in regression 
equalions Ihal estimate body densily (d). From this, FM can be calculated using the Siri 
equalion (103). 
FM = BW • (4.951 d - 4.50) 
Body mass index (BMI) or Quetelet's index (body weighU(body height)') is the most 
commonly used index of relative weighl. However, because lean body mass generally 
decreases in advanced age, while fat mass increases, body mass index cannot be used 
as a measure of body fal mass in older age groups. When corrected for age and sex, 
BMI and skinfold measurements are slrongly correlated (104) and can be used for Ihe 
eslimation of body fat in cross-seclional studies (105). 
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Bioelectrical impedance analysis 
The principle of BIA is that lean tissues, which mainly consist of electrolyte containing 
water, readily conduct an applied current, whereas fat conducts little current. This 
current of 800 ~lA at a signal frequency of 50 kHz is generated by a bioelectrical 
impedance analyzer and is applied to the patient through electrodes that are placed on 
the wrist and the ankle at one side of the body. After correct positioning of the patient 
and the electrodes, the impedance (or resistance, R) of the body is controlled by the low 
impedance lean compartment and is a function of the specific resistance of lean tissue, 
the cross-sectional area and the length of the lean compartment. Since water is the 
major component of the lean body compartment, TBW and FFM can be calculated from 
the measured impedance in good accordance with other methods of body composition 
assessment (106-110). However, the validation of the BIA method under different 
circumstances (hydration status), in different patient groups (normal, obese, growth 
hormone deficient, elderly), using different body impedance analyzers, differences in 
electrode placement and using different prediction formulas, remains a matter of debate 
(111-116). Also the validity of the basic equation is discussed in that it cannot detect 
changes in body composition unless they are considerable (117). The bioelectrical 
impedance method predicts body composition with an error that is comparable with the 
error using anthropometric techniques, and thus seems to have little or no advantage 
over simpler and less expensive techniques (114). 
Isotope dilution 
TBW can be determined by isotope dilution using isotopes of water like deuterium oxide 
(0,0) (118,119). The TBW tracer dilution method relies on administering an oral dose of 
labeled water and measuring its dilution in body water after equilibration. After 
equilibration urine samples are taken for measurement of dilution. Food intake shortly 
before and during equilibration must be avoided or corrected for, since this will expand 
the TBW pool. In the two-compartment model errors in the TBW measurement will be 
magnified when calculating fat mass (FM = BW - TBWI 0.73). Another difficulty 
associated with this method is that the hydrogen dilution space is greater than the water 
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space because of the exchange with labile hydrogen of protein and other body 
constituents (98). 
Dual energy x-ray absorptiometry (DXA) 
DXA is a non-invasive method of measuring bone and soft tissue body composition. 
DXA directly measures fat mass, lean tissue mass and total body bone mineral content. 
This equipment uses an X-ray source which produces a dual-energy beam with 
energies of 38 and 70 keV by K-edge filtering using cerium. The DXA system performs 
rectilinear scans over the entire length of the patient's body, beginning at the top of the 
head and moving downwards towards the feet. A total body scan takes approximately 
15-20 minutes and the subject receives less than 0.5 I'SV radiation exposure. The 
analysis software calculates percent body fat based on the ratio of soft tissue 
attenuation of the two x-ray energies. Also lean tissue mass and bone mineral content 
are measured (120-124). 
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1.5 Incidence, causes and features of the growth hormone deficiency 
syndrome in adults 
Most cases of hypopituitarism are acquired in adult life (Table 2). Most cases of adult 
GHD (GHDA) result from pituitary or peripituitary tumors or their treatment (126). The 
greater the number of anterior pituitary 
Table 2. Etiology of hypopituitarism 
in the adult 
Congenital 
Isolated 
Multiple 
Acquired 
Pituitary andperipituitary tumors 
Pituitary apoplexy 
Surgery! trauma 
X-ray therapy 
Infiltrations! infections 
Idiopathic 
Adapted from ref. 125 
hormone deficiencies, the more severe 
GHD turns out to be (in terms of peak 
GH after GH-stimulation testing) (127). 
The incidence of GHDA is not known, 
but indirect estimates based on the 
number of patients with pituitary tumors 
suggest that GHDA may affect ten 
people per million annually (128). Apart 
from this, also childhood-onset GHDA is 
recognized. These children, who did 
demonstrate an insufficient growth, have 
been treated in most cases with hGH in 
order to reach their final height. 
GHDA has become recognized as a 
specific clinical syndrome (28). It is 
associated with changes in body 
composition (1.5.1.), impaired physical 
performance (1.5.2.), reduction in bone mineral content (1.5.3.), disorders in lipid 
metabolism, impaired cardiac function with increased cardiovascular morbidity and 
mortality (1.5.4.), and decreased psychological well-being (1.5.5.). 
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1.5.1 Body composition 
GH-deficient children are relatively obese and a decrease in adipose tissue is one of the 
earliest noticeable changes after starting GH-replacement therapy (129-131). There are 
only a few studies in which body composition parameters of GHDA are more or less 
compared with controls (66,67,132-134). A control population should consist of patients 
with multiple anterior pituitary hormone deficits, without GHD, caused by a hypothalamic 
or pituitary disorder and its sequelae, such as operation and radiotherapy. However 
such a control population probably does not exist, since GH is the first and most 
commonly involved anterior pituitary hormone to become deficient in pituitary disease 
(127). The controls in the above mentioned studies, are therefore all healthy controls. 
Fat mass 
Body fat is increased and distributed more in a central than a peripheral pattern 
(67,133,134). 
Lean body mass 
There is a decrease in lean body mass (LBM) of approximately 4 kg as measured with 
whole body "'K counting (67). Predicted values were based on age-, sex-, height-, and 
weight matched controls. 
Skeletal muscle mass 
Skeletal muscle normally comprises approximately 50% of LBM. Compared to controls 
GHD adults have a decreased muscle to fat ratio in the mid-thigh as assessed by 
computerized tomography (CT) (66). Also with anthropometric methods a decrease in 
muscle mass can be demonstrated (133). 
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1.5.2. Physical performance 
Patients with GHD have lowered muscle size and strength. compared to normal controls 
(67,135). When GH replacement therapy is stopped in children, when adult height has 
been achieved, muscle size and strength decrease within several months (136). 
Initiation of GH replacement therapy in GHD adults causes an increase in lean body 
mass, 50% of which consists of muscle, while also exercise performance improves 
(137,138). 
When studied in a metabolic ward situation an increase in whole body protein turnover, 
protein synthesis and breakdown were found resulting in a positive nitrogen balance 
(32,61). After a substantial increase of total body protein mass a new steady state will 
be reached. 
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1.5.3. Bone turnover and bone mineral mass 
Prevalence of osteopenia in subjects with GHD of both childhood (139,140) and adult 
onset (141, 142) is high. Susceptibility for fractures is increased, which is compatible with 
the inverse relationship between bone mineral density (BMD) and fracture risk 
(143-145). The mechanism of the reduction in BMD as observed in untreated patients 
with GHD is uncertain. There does not appear to be a relationship between the duration 
of GHD and the degree of reduction in BMD. Age of onset rather than duration seems to 
be important in determining the reduction in BMD (142). A positive correlation between 
circulating insulin-like growth factor (IGF-I) and BMD in individuals with acquired GHD 
has been reported (146, 147). 
GH has both direct and indirect actions on bone. Protein anabolic effects of GH result in 
increases in both muscle mass and strength. GH increases gastrointestinal calcium 
absorption and increases the renal phosphate threshold, thereby providing the substrate 
for bone formation. GH activates bone remodeling by stimulating chondrocyte, 
osteoblast and osteoclast activities (29,148, 149). Based on these observations clinical 
studies were initiated to establish the potential effects of GH replacement therapy on 
bone turnover and bone mass. Several reports indicate that GH replacement results in a 
considerable increase of bone turnover as indicated by an increase of markers of bone 
resorption and bone formation (149-154). Long-term treatment wilh GH up to 30 months 
leads, after an initial downwards trend, to a sustained increase of bone mineral content 
(BMC) as measured in the axial and appendicular skeleton (155-158). In other words 
long-term GH replacement therapy appears to result in a favorable shift in the balance 
between bone resorption and bone formation. 
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1.5.4. Lipid metabolism, atherosclerosis and cardiac function 
Altered serum concentrations of lipids and lipoproteins are well-recognized risk factors 
for cardiovascular and coronary artery disease (The Framingham study, (159)). Such 
changes include increased concentrations of serum total cholesterol (160), low-density 
lipoprotein (LDL) cholesterol, and apolipoprotein B (apo B), an elevated apo B:A1 ratio, 
and a decreased high-density lipoprotein (HDL) cholesterol concentration. 
Atherosclerosis and cardiovascular morbidity and mortality seem more common in 
adults with hypopituitarism receiving routine hormone replacement but not growth 
hormone (128,143). In the case of multiple pituitary hormone deficiencies due to 
pituitary adenomas or after treatment with irradiation or surgery GHD is likely to be 
present (126,127). Therefore GHD might be a factor in this increased mortality from 
cardiovascular disease. 
In the normal population as well as in GHD the role of GH in the control of lipoprotein 
metabolism and atherosclerosis has not been fully elucidated. Most studies have shown 
modest hypercholesterolemia and hypertriglyceridemia in GHD children and adults 
(161'165). GH treatment did not exert effects on lipids and lipoproteins in patients and 
volunteers without GHD (166-168). In severe GHD patients there was a lowering of 
serum cholesterol levels during GH therapy (67,169). In another study a favorable 
increase of HDL-cholesterol levels, but also an unfavorable increase in serum Lp(a) 
lipoprotein was observed during GH replacement therapy (170-172). 
Apart from possible disturbances in lipid metabolism increased atherosclerosis was 
demonstrated among GHDA patients as established by high resolution ultrasonography 
of the carotid artery (173). Also, in GHDA a decrease in aortic distensibility was found 
(174). In animal experiments, this decrease in compliance could be reversed by the 
administration of growth hormone (175). Others found myocardial dysfunction as result 
of a reduction in left ventricular mass in GHDA patients (176,177). Myocardial 
contractility increased following short-term GH treatment in normal volunteers (178). In 
GHD patients an increase in left ventricular wall mass was found after six months GH 
replacement therapy (179). 
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1.5.5. Psychological well·being 
Reliable tests have been developed to measure health status. One of these tests. which 
is used frequently, is the Nottingham Health Profile (NHP) developed in the early 1980s 
(180). It is a self·rating questionnaire by which perceived health problems and their 
impact on task performance in the physical, mental and social spheres are measured. 
Part I of the NHP consists of 38 statements covering six sections, each of which refers 
to a separate area of functioning. The sections comprise physical mobility, pain, sleep, 
energy, social isolation, and emotional reactions. Respondents are required to read 
each statement and to tick either 'yes' or 'no', depending on whether that problem 
applies to them at the time. The questionnaire takes between five and ten minutes to 
complete. 
The sections contain between 3 and 9 items, each of which has received a certain 
scoring weight in order to make the maximum score per section 100. Thus a respondent 
affirming all the statements in one section would obtain a score of 100. Part II of the 
NHP consists of seven statements relating to the effect of health problems on 
occupation, jobs around the home, personal relationships, social life, sex life, hobbies 
and holidays. 
Several studies have established the validity and reliability of the NHP (181,182). 
Validity and reliability of the Dutch adaptation were found good, with exception of the 
section social isolation (183). 
When compared to several other questionnaires the NHP was the easiest to use and 
the most reliable in the sense of reproducibility and internal consistency. 
NHPand GHD 
Compared to controls GHD patients have a poorer quality of life. There were significant 
differences in the sections of physical mobility and social isolation. Interestingly no 
differences were found between patients with isolated GHD or GHD combined with 
deficiencies of anterior pituitary hormones (184). 
In another study significant decreases were found for GHDA patients in the sections 
energy, social isolation, emotional reactions and sex life (185,186). Treatment for six 
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months with GH in a group of patients with childhood and adult onset GHD, showed 
improvement in the overall scores of the NHP and in the subsection of energy versus 
placebo (185). 
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1.6. Future uses of growth hormone 
The proposed indications for GH therapy can targely be defined in three categories; the 
ones proven to be effective, the ones 
Table 3. Uses of growth hormone 
Conventional uses 
classical GHD 
chronic renal failure in children 
Turner's syndrome 
Nonconvenlional use 
non GHD short stature 
GHD adults 
obesity 
aging 
critical illness or injury 
glucocorticoid therapy 
osteoporosis 
Adapted from ref. 188 
possibly effective and the speculative 
ones (187). Since restrictions due to 
scarcity of supply have been lifted, more 
and more fields to study the effect of GH 
therapy have been proposed. Some of 
these and the original indications are 
listed in Table 3. 
In none of the reports on the final 
outcome of GH therapy of children with 
GHD, a normal mean height has been 
reached. The average mean height 
achieved was in general slighlly more 
than -2 SD (-12-14 cm) below the 
midparental mean height. Final outcome 
was negatively correlated with the 
degree of height loss at the onset of 
therapy, which implies that timing of the 
start of GH replacement is crucial 
(188,189). Growth failure is a major 
clinical complication of chronic renal failure (CRF). GH therapy in CRF in patients 
without requiring dialysis, with dialysis or after renal transplant was proven to be 
effective (190-192). Turner's syndrome in girls is a fairly common disorder, which is, 
among other features, characterized by short stature. In a large study, treatment with 
GH was responsible for an estimated increase in final adult height of 8 em (193). 
However, no final conclusions can be drawn at present concerning the actual gain in 
length due to GH treatment in this type of patients. In non GHD short stature data on 
the overall efficiency of GH therapy remain inconclusive. 
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GH replacement therapy in GHD adults will not be further discussed in this chapter. GH 
treatment in obese patients receiving hypocaloric nutrition, results in a nitrogen sparing 
effect which disappears after 5 weeks. Although cumulative weight loss, and body 
composition were not influenced by GH administration, the improvement in nitrogen 
retention may be beneficial in terms offatigue (194). 
Both GH deficiency in adulthood and normal aging are associated with decreases in 
protein synthesis and in the percent lean body and bone mass, and with increases in 
percent of body fat (28,66,195-198). Whole body protein turnover is decreased in these 
conditions (199). It is possible that a gradually reduced GH secretion and decreased 
IGF-Ilevels might account, at least in part, for one or more of the above effects of aging 
(44), and that some elderly people might benefit from treatment with GH (43). In several 
recent studies administration of GH to elderly subjects for periods varying from a few 
weeks to twelve months, resulted in improvements of nitrogen balance, in an increase in 
lean body mass, and in a decrease in percent body fat (60,200-205). 
In a controlled study in patients undergoing major gastrointestinal surgery, after which 
they were not fed for six days, patients were randomized to receive placebo or GH (0.1 
mg/kg.day). In the GH group there was a significant reduction in nitrogen excretion, and 
an increase in energy expenditure and fat oxidation. Protein turnover had increased, as 
reflected by an increased synthesis and breakdown resulting in an improved nitrogen 
balance (206). These latler findings were confirmed in patients who underwent elective 
cholecystectomy (33). 
When in major gastrointestinal surgery GH is combined with parenteral nutrition even 
a positive nitrogen balance can be achieved (207). In normal individuals a positive 
nitrogen balance was reached during hypocaloric intravenous nutrition, when combined 
with GH (208). GH improves the efficiency of nutritional support in patients after major 
operation (209-211). This was recently also found in patients after trauma (212). 
In patients with severe sepsis GH also did improve, but not reverse a negative nitrogen 
balance (213). 
In animal studies GH was found to improve mechanical strength of the rat colon after 
operation (214), of rat tibial fractures (215), and of skin wounds (216). These 
observations support improved wound healing, induced by GH administration. 
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The positive effects of GH on nitrogen balance in bum patients were already 
demonstrated in the early 1960s (57,217), and have been confirmed since (58). It was 
not until recently, that it was demonstrated, that GH therapy also leads to a significant 
decrease in donor-site healing time in severely burned children and a reduction in the 
length of hospital stay by more than 25% (218,219). 
Other positive effects on nitrogen balance were seen in patients that were catabolic due 
to treatment with glucocorticosteroids (62), cancer (220), and patients with infection 
of the human immunodeficiency virus and AIDS (221,222). 
GH increases bone turnover (29). However, trials in postmenopausal osteoporosis so 
far have been disappointing. This subject will be discussed more extensively in chapter 
6. 
Other potential indications for GH administration are ovulation induction and lactation 
failure. These will not be further discussed. 
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1.7 Safety of human growth hormone therapy 
Human GH extracted from cadaveric pituitaries has been shown in some instances to be 
contaminated with an infectious agent causing Creutzfeld-Jacob disease. Since the 
introduction of recombinant human GH this potential hazard has become eradicated in 
newly treated patients and will not be further discussed (see chapter 1.1). However, at 
the time it came unexpectedly and it reminds us of being alert to possible long-term, side 
effects of GH therapy. 
There is a fundamental pharmacological difference in the treatment of patients with 
pituitary disease as compared to most other medical treatments, in the fact that in these 
patients deficiencies are replaced by hormonal substitutes, which represent normal 
hormone secretion. In patients with hypopituitarism, there is a necessity to replace 
thyroid, adrenocortical, gonadal and posterior lobe function in a way that mimics 
physiology as closely as possible. GH replacement therapy in GHD adults causes 
remarkably few side-effects, most of which are minor or transient and improve after dose 
reduction, suggesting that they are dose-dependent. The most frequently reported side-
effects are related to water retention, like edema, arthralgia and carpal tunnel syndrome. 
Another reported complaint is transient muscle ache. 
Long-term safety reports concerning GH replacement therapy are not available in 
adults. In 1988, there have been reports from Japan of an increased risk of leukemia in 
children (223). In a subsequent large survey, however, it was found that the risk of 
acquiring leukemia during GH therapy is not higher than that in the general population 
(224). In 1993 there was a report that GH therapy was associated with benign 
intracranial hypertension in 22 children and one adult (225). All patients had developed 
papilledema, while 21 of them presented with headache and/or visual changes. 
Cerebrospinal fluid pressure was increased in 11 of 12 patients in whom values were 
reported. Papilledema and symptoms of intracranial hypertension resolved in all patients 
after treatment was stopped. The fact that these reported cases began to appear only in 
1986 may be due to the trend toward the use of higher and more frequent doses of GH 
and the expansion of the indication for use beyond GH replacement, which followed the 
33 
Introduction 
introduction of recombinant GH in 1985. So far, there have been no such reports in 
adults during GH replacement therapy. 
GH dose in adult replacement therapy has decreased lately, in comparison with the 
initial studies (66,67,154,158). There is no good parameter to define the optimal GH 
dose. However, individual GH dose adjustment, with careful monitoring of side effects, 
until high normal IGF-I levels are reached, might prove a good strategy to obtain 
maximum biological effects of GH therapy in GHD patients. 
In elderly men with lowered IGF-Ilevels, GH treatment caused carpal tunnel syndrome, 
gynaecomastia and hyperglycemia (226). Apart from the fact that these men were 
probably not GH deficient, the GH doses used were supraphysiological (30 Ilg/kg three 
times a week, 0.243 IUlkg.week) even for GHD. GH decreases the sensitivity to insulin. 
Therefore an individual, who is in a pre-diabetic state, with impaired insulin release, 
might develop clinically recognizable insulin deficiency after GH treatment is started. GH 
does not impair insulin secretion. Thus GH may reveal diabetes mellitus, but does not 
cause it. 
In conclusion no deleterious side-effects of long-term GH therapy have been observed 
or are to be expected as long as the GH dose is within the physiological range. 
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1.8 Scope of the thesisl Aims of the studies 
Several aspects of the GHD syndrome, GH replacement therapy, and GH therapy were 
further investigated in this thesis. 
At first several aspects of the GHD syndrome will be studied in a large group of patients 
with childhood and adult onset GHD. Is there a difference in the clinical symptomatology 
among these two groups of GHD patients, other than their length and the age of onset 
of GHD? (chapter 2). 
Thereafter the acute, initial effects of short-term GH replacement therapy will be studied 
in GHDA patients on nitrogen balance, sodium and potassium balance, IGF-I and 
IGFBP-3 and body composition. What is the degree of nitrogen and sodium retention 
and how long does it last? Does measurement of IGFBP-3 help in finding the optimal 
dose of GH replacement therapy? Are the changes in fat mass as measured by 
bioelectrical impedance analysis real or misleading? (chapter 3). 
Subsequently the effects of GH replacement are studied on renal phosphate handling, 
bone turnover and bone mineral content. These effects are compared to GH 
replacement therapy in combination with pamidronate, an inhibitor of bone resorption. 
Does pamidronate influence these parameters; is the combination of GH and 
pamidronate beUerwith regard to the initial effects in bone mineral content? (chapter 4). 
In chapter 5 the usefulness of GH as an adjuvant to pamidronate is studied in patients 
with postmenopausal osteoporosis. Elaborating on the impressive effects of GH on bone 
in GHD adults, can GH also play a role in the treatment of postmenopausal 
osteoporosis? 
Finally the effects of long-term GH replacement therapy are studied in patients with 
adult onset GH-deficiency. Special emphasis is directed at several aspects of body 
composition assessment. Which method of body composition measurement is most 
suitable in the follow up of GHD patients on long-term GH replacement therapy? Will 
initial beneficial effects be maintained during long·term treatment? Are side-effects 
clinically important and persistent? (chapter 6). 
In the concluding chapter the results obtained are summarized and a synthesis is 
formulated on the current use of GH replacement therapy in GHD adults (chapter 7). 
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2 Adult Growth Hormone Deficiency Syndrome Patients Demonstrate 
Heterogeneity Between Childhood Onset and Adult Onset 
51 
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ABSTRACT 
Background and Methods. The recognition of a clinical syndrome of growth hormone 
deficiency (GHD) in adulthood is now gaining acceptance. Its onset may be during 
either childhood (CO) or adulthood (AO) but potential differences in patient 
characteristics and symptoms, as well as biochemical parameters have not 
previously been explored. In this study the baseline data from CO (idiopathic; N=74; 
mean age 29 yrs) and AO (acquired; N=99; mean age 44 yrs) patients enrolled in a 
trial of GH administration in GHD adults have been compared. 
Results. Final height in CO patients was considerably less than in AO patients (161 
vs. 171 cm; P<0.001), while their body weight was less (64 vs. 85 kg). Body mass 
index was lower in CO patients (24 ± 5 vs. 29 ± 5 kg/m'; P<0.001) and lean body 
mass corrected by height was also lower (263 ± 65 vs. 333 ± 72 g/cm; P<0.001). 
Percent body fat was similar for both groups, waisUhip ratio was significantly less in 
CO than AO (0.90 ± 0.09 vs. 0.96 ± 0.06; P<0.001), but triceps skinfold thickness 
was not different. Serum IGF-Ilevels in CO were lower than in AO (55 ± 57 vs. 71 ± 
35 ng/ml, P<0.001) and 92 % of CO and 85 % of AO patients had values below the 
normal range. The IGFBP-3 concentration was significantly lower in CO patients 
(1534 ± 1007 vs. 2393 ± 953 ng/ml, P<0.001) and 76% of CO but only 35% of AO 
had values below the normal range. The correlation between IGF-I and IGFBP-3 
was much stronger in CO (r=0.93) than in AO (r=0.57). Osteocalcin levels were 
elevated in CO and normal in AO GHD patients (8.6 ± 3.3 vs. 5.6 ± 3.0 ng/ml; 
P<0.001; normal adult range 1.8 - 6.6). Serum lipid concentrations were much closer 
to normal values in CO than in AO patients: elevated cholesterol levels were 
observed in 52 % of CO, and 78 % of AO patients, while lowered HDL-cholesterol 
was found in 54 % of CO, and 74 % of AO patients. The quality of life (QoL), 
evaluated with the Nottingham Health Profile questionnaire, showed abnormal 
dimension scores for all 6 subscales both in CO and AO patients, but the degree of 
distress in the AO patients was significantly higher for physical mobility and energy 
levels in comparison to CO patients. 
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Conclusions. The results demonstrate considerable differences in the clinical and 
biochemical presentation of the adult GHD syndrome. Adult patients with idiopathic 
CO GHD show somatic underdevelopment similar to pituitary dwarfism: they remain 
too small, have generalized obesity and a lowered muscle mass, elevated 
osteocalcin levels, marginal abnormalities in their lipid metabolism and are relatively 
content with their life. However, somatic development is complete in AO GHD 
patients, who have previously experienced the full advantage of health and physical 
maturation. With GHD most of them become obese, with a central abdominal 
localization, and the majority have lowered HDL-cholesterollevels indicating the risk 
of premature atherosclerosis. Subjectively they experience a greater loss in their 
quality of life. These metabolic and body composition abnormalities as well as the 
subjective psychological distress caused by the lack of GH in previously healthy 
adult individuals suggests a beneficial effect of hGH replacement therapy in AO 
GHD. For CO GHD individuals hGH therapy might in retrospect have been better 
continued into adulthood after the end of skeletal growth in order to induce full 
somatic maturation. 
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INTRODUCTION 
The estimated prevalence of growth hormone deficiency (GHD) in children in the 
western world is about 1 in 12,000, which amounts to 85 per million inhabitants (1). 
The additional prevalence of hypopituitarism acquired in adulthood, due to pituitary 
and peri-sellar tumors and/or after radiotherapy is unknown. It seems reasonable, 
however, to assume that a total of about 250 adults per million are GHD. 
GHD in children can be easily recognized as a failure to grow and the diagnosis and 
therapy of childhood "hypopituitary dwarfism" have historically been focused on 
height assessment. The main goal of hGH therapy in children has always been to 
achieve a normal adult height. Other symptoms of childhood GHD such as lowered 
muscle mass/strength, fat accumulation, lowered bone density, and poor social 
adaptation, have not played an important role so far. 
The concept of a clinically recognizable syndrome of GH deficiency in adulthood 
has gained widespread acceptance after the initial reports on the beneficial effects 
of long-term GH replacement therapy in GHD adults (2-4). Decreases in quality of 
life, muscle strength, bone mass, as well as changes in body composition indicating 
an increased amount of body fat were reported to be reversible with GH treatment in 
most patients (2,3,5-8). In addition, recent epidemiological studies indicate that 
there is an increased (doubled) incidence of cardiovascular mortality in patients with 
hypopituitarism who are receiving optimal replacement therapy with cortisol, thyroxin 
and sex steroids (8). This increased mortality seems to be directly related to the 
development of premature atherosclerosis in hypopiluitary patients as indicated by a 
study with high resolution ultrasonic imaging of the carotid and femoral arteries (9). 
Measurements of serum lipids point to abnormalities in total cholesterol (increased) 
and HDL-cholesterol concentrations (decreased) in a considerable proportion of 
untreated GHD adults (2,10-12). 
No studies have previously been designed to investigate whether the clinical 
syndrome related to GHD in adulthood might present with signs, symptoms and 
biochemical parameters which differ between patients who became GHD in 
childhood (childhood onset: CO) and patients who became GHD in adulthood (adult 
onset: AO). In the present study we examined a number of clinical and biochemical 
aspects of the GHD syndrome in adulthood in relation to time of onset. 
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METHODS 
Patients 
The results presented were obtained from the baseline assessment of 173 adult 
patients (18-60 years of age), who were enrolled to participate in a randomized, 
double-blind, placebo-controlled study on the safety and efficacy of hGH 
replacement therapy in adults with GHD. The study was sponsored and monitored 
by Lilly Research Centre Ltd. (Windlesham, Surrey, UK). It was a multinational, 
multicentre study with 12 participating institutions in 10 European countries. 
Patients to be included in the study had GHD arising during adult life (AO) and 
present for at least one year, or had GHD arising and treated during childhood (CO) 
but had not been treated with hGH in the previous two years. For the diagnosis of 
GHD a peak GH value less than 5 g/I in a standard stimulation test was required as 
an inclusion criterion. IGF-I and/or IGFBP-3 values were not taken into account for 
the diagnosis. Replacement therapy with cortisol, thyroxin, sex steroids or 
vasopressin had to be stable for at least six months prior to the start of the study, 
and no patients with hypertension were included. 
Anthropometric measurements 
Height was measured for each patient and the distribution within each group was 
calculated and compared to the distribution of reference values measured for a 
normal, fully-grown population (13). Total body weight was also measured and the 
distribution for AO patients was compared to weight for height reference standards 
from a normal population (14). A similar comparison for the CO patients could not be 
carried out since the height distribution for this group was predominantly low and did 
not match a normal adult population. Weight ranges were also evaluated using body 
mass index (BMI; Quetelet's index) calculated from weighUheight' (15). Waist 
circumference was measured at the level of the umbilicus and hip circumference at 
the level of the greater trochanter, and the waisUhip ratio was calculated for each 
patient. Skinfold thicknesses were measured with calipers, at the triceps, biceps, 
subscapular and supra iliac sites and for each patient these values were added 
together to give a sum of skinfolds value. 
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Body composition 
Bioelectrical-impedance was measured and total body water was calculated from 
the formula provided by the manufacturer of the body composition analyzer (Holtain, 
Dyfed, UK) as: 
Total body water = «Height' / Bioelectrical impedance) x 0.585) + 1.625 
Assuming that fat mass is anhydrous and that lean body mass contains 730 g 
water/kg, then: 
Lean body mass = Total body water / 0.73 
Fat mass was calculated from the difference between total body weight and lean 
body mass (16,17). 
Serum Biochemistry 
Serum samples were taken from each patient in a fasting state. Insulin-like growth 
factor-I (IGF-I) was measured by an IGFBP-blocked RIA (18) using a kit supplied by 
BioMerieux (Nurtingen, Germany) and insulin-like growth factor binding protein-3 
(IGFBP-3) was measured by a two-site immunoassay (19). Osteocalcin levels and 
insulin concentrations were measured by slandard radioimmunoassays. Total 
cholesterol, high density lipoprotein (HDL) cholesterol, apolipoproteins Ai and B, 
triglyceride and glucose concentrations were each measured by standard 
techniques. Glycosylated hemoglobin (HbA1 C) was assessed by high-performance 
liquid chromatography using routine methods. 
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Quality of life assessment 
QoL was assessed from the Hospitat Anxiety and Depression scale (20) and from 
the Nottingham Health Profile (NHP) developed by Galen Research (Manchester, 
UK). The HAD scale is a self-rating scale which provides separate measures for the 
two constructs, anxiety and depression. For each construct a score below 8 is 
normal, a score between 8 and 10 is "borderline" and a score above 10 indicates a 
probable disorder of the relevant mood. The NHP data was analyzed by Galen 
Research for each of the subsections and these were compared for each group with 
scores found in other chronic illnesses. NHP scores are inversely related to the 
patient's QoL, i.e. a higher score indicates a worse QoL. 
Statistical Methods 
For the comparison of CO and AD, the analysis was performed on rank transformed 
data using an analysis of variance model, incorporating effects of onset, gender, 
and the onset-by-gender interaction. The following model was used: 
where: Y;jk= measurement for patient k within onset group i and gender j, ~,= overall 
mean, 0; = onset group i, Gj = gender j, OG;j = onset-by-gender interaction, e;jk= error 
term. Tests for differences between genders, for AD and CO patients separately, 
were made by using the overall mean square error from the full model using the 
CONTRAST statement in SAS (21). Spearman correlation coefficients were used to 
examine the linear relationship between two variables. In addition to the formal 
hypothesis tests, the distributions of certain parameters were summarized (using 
percentiles of the distribution), and compared to normative data available from the 
published literature. 
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RESULTS 
Etiology and diagnostic criteria 
The spectrum of causes of GHD (Table I; in 7 CO and 1 AO patients no etiological 
diagnosis was available) was entirely different between the two groups of patients. 
Idiopathic GHD, isolated or multiple, was reported in 89.5%, tumor in 4.5%, and 
other causes in 6% of CO GHD subjects. Concomitant medication of thyroxin, 
cortisol or sex steroids was used in 54%, 28%, and 60% respectively of all CO 
patients. The duration of GHD could not be determined, but in all CO patients the 
diagnosis had been made during early childhood, and all patients had been 
previously treated with hGH to final height. A minority of CO GHD adults had 
become GHD around puberty, mainly due to craniopharyngioma (4.4%). 
(Peri-)pituitary tumors were reported as the cause of GHD in 82 % of AO cases with 
pituitary adenomas predominant, 56%, followed by 
(continued page 60) 
Table I. Etiology of Growth Hormone Deficiency (GHD) in Childhood and 
Adult Onset Patients. 
Childhood Onset n % 
Idiopathic 
Isolated growth hormone deficiency 19 28.4 
Growth hormone plus TSH deficiency 7 10.4 
Growth hormone plus LH/FSH deficiency 4 6.0 
Multiple deficiency 30 44.8 
Trauma, Empty sella, Post-tubercular condition 4 6.0 
Craniopharyngioma, Dysgerminoma 3 4.4 
Adult Onset 
Active Adenoma 30 30.6 
Inactive Adenoma 25 25.5 
Craniopharyngioma 19 19.4 
Dysgerminoma, Pinealoma, Epidermoid Cyst 6 6.1 
Post-Tubercular Condition, Histiocytosis 2 2.0 
Trauma, Sheehan Syndrome, Empty Sella 9 9.2 
Idiopathic, Hypothalamic Origin 7 7.2 
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Table II. Demographic, anthropometric and body composition data, and circulating IGF~I and IGFBP~3Ievels in 173 adult GHD patients. 
Total Males Females 
CO AO CO AO CO AO 
(n=74) (n=99) (n=55) (n=61) (n=19) (n=38) 
A. Demographic and anthropometric data 
Age (years) 28.8 ± 8 43.5 ± ga 28.6 ± 8 43.5 ± 10 29.5 ± 8 43.4 ± 7 
Height (em) 160.8 ± 10.0 171.0 ± 6.9' 163.9 ± 10.0 176.1 ± 6.9' 151.9 ± 7.6 162.4 ± 5.5 
Weight (kg) 63.7 ± 17 84.9 ± 17a 66.6 ± 17 88.7±15' 55.4 ± 13 78.6 ± 19 
BMI (kg/m2j 24.5 ±5.5 28.9 ± 5.2' 24.7 ± 6.0 28.5 ± 4.0' 23.9 ± 5.0 29.6 ± 6.0 
Waist/Hip ratio 0.90 ± 0.09 0.96 ± 0.05' 0.91 ± 0.06 0.97 ± 0.06' 0.86 ± 0.15 0.93 ± 0.05' 
B. Body composition 
Bio~impedance (ohm) 530 ± 90 447 ± 88' 506 ± 93 418±80' 599 ± 86 493 ± SOc 
Body fat mass (kg) 20.2 ± 10 27.6 ± 12' 19.8 ± 11 24.8±11' 21.5±10 32.3 ± 14' 
Lean body mass (kg) 43.5 ± 12 57.2 ± 14a 46.8 ± 12 64.0 ± 13' 33.8 ± 5 46.3 ± 7c 
Percent body fat 31.1 ±11 31.9±13 28.9 ± 11 27.4 ± 12 37.5±10 39.0±11' 
Sum of skinfolds (mm) 83.3 ± 37 87.5 ± 31 83.2 ± 41 80.3 ± 76 83.5 ± 28 99.3 ± 34b,c 
C. Serum IGF~I and IGFBP..J concentrations 
IGF-I (ng/ml) (nonmaI91-340) 56 ± 58 71 ± 35' 61 ±62 82±37 41 ±42 53 ± 23' 
IGFBP-3 (ng/ml) (nonmal 1950-3800) 1534 ± 1007 2393 ± 953 1564 ± 991 2462 ± 904 1446 ± 1073 2283 ± 1028 
Osteocalein (ng/ml) (normal 1.8-6.6) 8.6 ± 3.3 5.6 ± 3.0' 8.8 ± 3.5 6.1±2.6 7.8 ±2.5 4.9 ± 3.4 
a P<0.001 vs. CO 
b P<O. 001 vs. CO Males 
c P<0.001 vs. AO Males 
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Table III Height distribution In CO and AO eaUents 
Percentile 
Height (em) 3% 10% 25% 50% 75% 90% 97% 
Adult Onset 
Males 165.0 167.0 171.9 175.5 182.0 186.5 188.0 
Females 155.0 155.8 158.0 162.0 166.3 170.6 172.0 
Childhood Onset 
Males 142.2 150.0 157.4 163.0 173.2 177.2 181.0 
Females 137.8 141.5 145.2 153.0 158.3 163.2 164.0 
Referencea 
Males 166.6 167.7 172.2 177.5 182.5 187.9 192.1 
Females 151.6 156.0 160.8 165.1 168.2 171.9 175.1 
8Reference values from Prader Swiss Growth Standard (13). 
craniopharyngiomas, 19%. Concomitant medication of thyroxin, cortisot, and sex 
steroids was used in 83%, 79% and 86% of all AO patients, indicating a high 
incidence of other anterior pituitary hormonal insufficiencies. The duration of GHD in 
AO subjects, was 8.9 ± 7.1 years (range 0.45 - 32.1). 
For the biochemical diagnosis of GHD, standardized GH provocation tests were 
used. The most frequently performed tests were the arginine (AO: n=31; CO: n=24), 
the insulin (AO: n=42; CO: n=3) and the ciani dine test (AO: n=1; CO: n=31). Other 
test substances used were L-dopa, GHRH and glucagon. The highest reported peak 
GH values were 4.3 and 4.6 gil in AO and CO patients respectively. 
Demographic and Anthropometric Data 
CO patients were significantly younger (P<O.001, Table IIA) and shorter (P<O.001) 
than AO GHD patients, and male patients were taller than females in both groups. 
The height distribution of the AO GHD patients was almost identical to that of the 
reference standard for both male and females. However, for the CO GHD patients 
approx. 50% of both male and females had height values below the 2 SD range for 
the normal adult reference population (Table III). 
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Body weights were significanlly higher in AO than in CO GHD patients (P<O.001; 
Table IIA) and in both groups males were heavier than females (P<O.001). For AO 
subjects the distribution of body weights indicated that more than 25% of both males 
and females had values higher than the upper 2SD range of the reference 
population (14). No adult weight reference standard can be used for a height 
distribution similar to that of the CO subjects. 
CO patients had a significanlly (P<O.001) lower BMI compared to AO GHD patients 
(Table IIA), although again it is difficult to compare BMI values between the groups 
due to the short stature of CO subjects. In AO, almost 40% of the patients, males as 
well as females, had a BMI value above 30 kglm' (> 85% for a normal population = 
obesity grade II), (22) while more than 10% of them had a BMI value higher than 36 
(> 95% for a normal population obesity grade III). In CO subjects, only 10% of the 
patients had a value higher than 30 kg/m'. Three of 74 CO patients (4.1%) and 
21/99 AO GHD patients (21.2%) had a body weight above 100 kg. 
The waisUhip ratio, shown in Table IIA, was significanlly (P<O.001) lower in CO 
individuals compared to AO patients, though both CO and AO subjects had a 
waisUhip ratio significanlly (P<O.001) higher than the value reported in normal 
individuals, 0.85 ± 0.04 (22,23). There was also a significant gender difference in 
waisUhip ratio for both CO and AO groups, males having significanlly higher values 
than females (P=O.022 and P=O.007 respectively). 
Body Composition 
Mean values of body composition measurements are presented in Table liB. 
Although on a weight basis CO subjects had less body fat than AO GHD patients 
(P<O.001), the values for percentage body fat were very similar between the two 
groups, females having a higher amount than males in both CO and AO (Table IV). 
Compared with values from a normal age- and sex-matched population assessed 
with the same methodology, (24-28) CO as well as AO patients have significanlly 
more body fat mass and percent body fat. 
CO subjects also had significanlly less lean body mass than AO on a net weight 
basis (Table liB) and males had significanlly (P<O.001) higher values than females 
61 
Heterogeneity between adult onset and childhood onset GHD 
in each group. Total lean body mass in CO GHD individuals was decreased 
(P<O.01) in comparison with reference standards, (56.5 ± 2.3 kg) (24-26) but in AO 
GHD patients lean body mass was not different from the average of the reference 
population. Calculation of the lean body mass /height, in g/cm, (29) also indicated 
that CO patients had significantly less lean body mass per unit height than AO 
patients (Table IV), males having a higher value than females in both groups. On 
the percentile distribution, the 90% value for both sexes in CO, 337 g/cm, lies 
between the 50% and 75% value for both sexes in AO, which indicates that per unit 
height AO subjects may have up to 20% more lean mass. In AO, the range of values 
of g/cm is not different from that of an adult age-matched reference population in 
which lean body mass was assessed by hydrodensitometry (28). 
Additional information on body fat distribution was obtained from skinfold 
measurements. There were no significant differences between AO and CO for sum 
of skinfolds (Table liB) or for the distribution of triceps skinfold thickness. 
IGF-I and IGFBP-3 
Mean IGF-I levels (Table IIC) were lower in CO than in AO GHD patients (P<O.001) 
although the level for each group was below the normal adult reference range (18). 
The individual IGF-I values in AO and CO ploUed versus age are presented in 
Figure 1 in relation to the 5% and 95% range of a normal population (18). IGF-I 
levels were below the 2SD range in 92% of the CO patients and in 85% of the AO 
patients. Interestingly IGF-Ilevels in males were significantly higher than in females 
in AO (P<O.Oot) but not in CO (P=O.172). In CO but not in AO patients IGF-I levels 
were significantly and negatively correlated with age (Table V). The decline with age 
in CO subjects is dramatic: at age 40 to 50 IGF-Ilevels are in the range measured in 
normal subjects of age 80 years and beyond (18). Although in AO there was no 
correlation with age, there was a significant negative correlation with duration of 
GHD (Table V). 
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Table IV Distributions of bod~ com~ositlon ~arameters 
Percentile 
Percent body fat (%) 10% 25% 50% 75% 90% 
Total CO 19.0 27.1 32.0 37.7 41.7 
AO' 17.8 26.1 33.4 40.5 45.7 
Males CO 17.5 26.0 30.3 34.3 40.1 
AO 15.7 23.0 30.0 35.1 39.0 
Females CO' 23.6 30.8 37.7 43.3 53.1 
AO' 27.2 34.3 41.6 45.7 51.4 
Lean bod~ mass I Height (g/cm) 
Total CO 202 233 258 297 337 
AO' 250 281 315 376 439 
Males CO 221 247 266 324 342 
AO 276 308 354 415 464 
Females COb 169 201 227 250 263 
AO' 225 257 281 310 338 
Trice~s skinfold thickness {mm) 
Total CO 10.0 13.5 19.0 26.0 34.0 
AO 10.1 12.2 16.2 21.2 33.0 
Males CO 9.2 11.5 15.6 19.2 34.6 
AO 9.7 12.4 16.0 23.0 25.2 
Females COb 12.0 16.4 19.0 27.8 32.4 
AO' 15.0 19.0 26.0 32.2 42.2 
a P<O.OS, CO vs AO; 
b p<O.OS, CO male vs CO female 
c P<O.05, AO male vs AO female. 
Table V Correlation of IGF-I and IGFBP-3 levels with demogra~hic and bod~ comeosition data 
Childhood Onset Adult Onset 
IGF-I IGFBP-3 IGF-I IGFBP-3 
P P P P 
Duration -0.35 <0.001 -0.29 0.007 
Age -0.53 <0.001 -0.53 <0.001 -0.18 0.078 - 0.05 0.650 
Height 0.30 0.010 0.32 0.005 0.52 <0.001 0.23 0.035 
Weight 0.34 0.003 0.37 0.001 0.16 0.111 0.21 0.035 
Lean body mass 0.46 <0.001 0.47 <0.001 0.36 <0.001 0.29 0.004 
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Mean IGFBP-3 levels were significantly higher in AD compared to CO (P<O.001) but 
there was no gender difference within each group. Individual IGFBP-3 values in AO 
and CO, plotted versus age, are presented in Figure 2 and were below the normal 
range in 76% of CO patients and in 35% of AO patients. Similar to IGF-I, IGFBP-3 
levels were negatively correlated with duration of GHD in AO (P=O.OO7), and with 
age in CO (P<O.001). 
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Fig.3 The relationship between IGF-I and IGFBP-3 levels in AO (r-O.S6; P < 0.001 ) and CO GHD 
patients (r-O.93; P < 0_001). 
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In Figure 3 the relationship between IGF-I and IGFBP-3 levels is shown for CO and 
AO GHD patients, separately. In each group IGF-I and IGFBP-3 were significantly 
correlated, but the correlation was much stronger in CO (r=0.93; P<O.001) than in 
AO patients (r=0.58; P<O.001). Both IGF-I and IGFBP-3 values were positively 
correlated with height, weight and lean body mass in CO patients, but for weight this 
relationship was less ciear in AO (Table V). 
Osteocalcin 
The mean serum osteocalcin level in CO GHD patients was 8.5 ± 3.3 ng/ml, which 
was above the normal range (Table IIC) and significantly (P<O.001) greater than the 
value in AO (5.6 ± 2.9 ng/ml) which was within the normal range. Individual analysis 
showed that elevated serum osteocalcin levels were present in 73% of CO and 30% 
of AO GHD patients. 
Lipid values 
Fasting serum cholesterol and other lipid concentrations are summarized in Table 
VIA. In comparison to CO subjects, the AO patients had significantly higher total 
cholesterol (P<O.001) levels and marginally lower HDl cholesterol values 
(P=O.071). Analysis of the total cholesterol concentrations in comparison with age-
and sex-matched controls showed that 53% of the CO and 78% of the AO GHD 
adults had levels above the normal range. HDl-cholesterol levels were below 
normal in 54% of CO and 70% of AD individuals. In AO subjects HDl-cholesterol 
levels were negatively correlated to body weight (r=-0.32, P=O.002), BMI (r= -0.27, 
P=O.01) and waisUhip ratio (r=-0.25, P=O.02). Similar correlations were found for CO 
although they were less significant. There was no significant difference in mean 
serum apolipoprotein At between the groups but apolipoprotein B was significantly 
(P=O.022) less in CO than in AO. 
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Table VI lipid values and glucose homeostasis in GHD patients 
Total Males Females 
CO AO CO AO CO AO 
A. Lipids 
Total cholesterol (mgldl) 
(normal 150-200) 
217 ± 54 240 ± 53a 212 ± 55 237 ± 52 227 ± 49 247 ± 55 
HDL-cholesterol (mgldl) 35.9 ± 12 31.9±11 35.0 ± 11 30.0 ± 10 38.2 ± 14 35.3 ± 11 
(normal males: 35-55, 
females: 45-65) 
Apolipoprotein A1 (mgldl) 148 ± 25 148 ± 29 147 ± 24 141 ± 28 152 ± 26 161 ± 28 
(normal 115-190) 
Apolipoprotein B (mgldl) 124 ± 38 140 ± 43 123 ± 39 137 ± 37 126 ± 39 145 ± 54 
(normal 70-160) 
Triglycerides (mgldl) 130 ± 88 191 ±171 140 ± 98 183±101 106 ± 53 205 ± 252 
(normal 40-1752 
B. Glucose Homeostasis 
Fasting glucose (mmol/I) 4.6 ± 0.9 4.4 ± 0.8 4.7 ± 0.8 4.4 ± 0.9 4.3±1.1 4.3 ± 0.6 
Fasting insulin (mU/ml) 13.9±8.1 16.7 ± 11.6 14.5 ± 8.6 15.6 ± 8.4 12.9 ± 6.7 18.8±15.4 
HbA,C (%) 5.02 ± 0.66 5.16 ± 0.54a 5.07 ± 0.71 5.18 ± 0.52 4.85 ± 0.44 5.13±0.58 
a P< 0.001 vs CO 
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Glucose Homeostasis 
Mean fasting glucose, insulin and glycosylated hemoglobin (HbA,C) concentrations 
are shown in Table VIB. There were no significant differences between CO and AO 
patients in the measurements for fasting glucose and insulin. Fasting insulin 
concentrations in AO subjects were significantly correlated with weight (P<O.001), 
BMI (P<O.001), body fat mass (P<O.001) and waisUhip ratio (P=O.016) but in CO 
these correlations were absent or much weaker. HbA,C levels were lower in CO 
than in AO patients (P=O.031), but were within the normal range. Glucose levels 
measured 120 min. after an oral glucose load were above 7.8 mmolll in 3/61 (4.7%) 
of CO and in 11/85 (11.5%) of AO patients. This prevalence of impaired glucose 
tolerance is not different from the normal population. 
Quality of life assessment 
For the HAD measurements, 1/65 (1.5%) of the CO patients had a score between 8-
10 and no patients higher than 10. In the AO group there were 10/97 (10.3%) 
patients with a score between 8 and 10, and 6/97 (6.2%) patients with a score 
higher than 10. The incidence of anxiety and depression in AO GHD patients was 
higher, than in CO individuals (P<O.01 and P<O.01 respectively). 
Baseline mean NHP dimension scores are presented in Table VII, together with the 
95% confidence intervals of these data. Also shown are the normal values of a 
reference population, derived from a large survey of a random population in central 
England (30-32) and carefully matched with regard to age and gender with each 
group of GHD patients in this study. Both the CO and AO onset patient groups score 
higher than the reference population on all six sections of the NHP. It is also evident 
that the CO patients generally had lower levels of distress than the AO patients. 
These differences were statistically significant for the physical mobility and energy 
level sections (Table VII). 
In Figure 4 the mean baseline NHP scores for these AO and CO GHD patients are 
compared with mean scores for patient groups with other chronic illnesses: 
rheumatoid arthritis (33), breast cancer (34), ischemic heart disease (35), and 
diabetes (36). 
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Table VII. Baseline mean NPH scores and 95% confidence intervals (CI) in CO and AO patients, as well as the mean reference 
level of age- and sex-matched controls 
Childhood onset Adult onset 
Mean ± SD 95% CI Reference Mean±SD 95% CI Reference 
level level 
Social isolation 5.9 ± 10.5 3.2 - 8.6 4.6 6.0 ± 13.0 4.7-10.1 5.1 
Physical mobility 10.5±14.0 4.7-12.9 1.4 18.4 ± 21.9a 12.8-21.7 3.4 
Emotional reaction 17.5±15.0 9.4 -18.6 8.5 15.8 ± 14.6 11.3 -18.1 9.6 
Energy level 15.8 ±25.7 8.6 -20.9 6.4 24.2 ± 29.2a 22.0 - 34.7 12.0 
Sleep 15.8 ± 18.4 9.4 - 20.1 8.5 18.5 ± 17.8 15.8 - 25.6 12.1 
Pain 10.5 ± 15.7 4.5 -11.9 2.8 11.6±17.5 6.3 -12.7 5.0 
a P<O.01 vs CO 
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Fig. 4 A comparison of the mean scores of the sections of the Nottingham Health Profile 
queslionnaire for Quality of Life in a number of chronic diseases and those in patients with 
adult onset and childhood onset Growth Hormone Deficiency (GHD). 
DISCUSSION 
The results described in the present study confirm the existence of "the clinical 
syndrome of GHD in adulthood", as defined by Sonksen's group (4), However, the 
pathogenesis and natural history of the GHD disease is different between AO and 
CO patients and although both groups exhibit symptoms of this syndrome, the 
magnitude and quality of the symptoms differ substantially between the two, 
Idiopathic growth hormone deficiency is the most common cause of GHD in 
childhood (2-4) and this is confirmed in our adult CO population in which only a 
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small percentage had acquired GHD. In AO patients, GHD was almost entirely due 
to pituitary organic disease and its pathogenesis and diagnosis are well defined by 
clinical criteria. 
Decreased or low normal IGF-I levels have been reported previously in adult 
patients with GHD (37-39). Most of the circulating IGF-I is bound to specific binding 
proteins (IGFBPs), the predominant form in blood being IGFBP-3 (40,41). In 
childhood and adolescence, IGFBP-3 measurements are reliable indicators of GH 
secretory activity and a useful tool for GHD diagnosis (18). In the present patient 
population the IGF-I and IGFBP-3 levels clearly separate the two entities of CO and 
AO GHD. In CO patients, both levels were significantly lower than in AO patients 
and were strongly correlated, i.e. the relationship remained similar to that found in 
childhood (18). Also, their actual values were strongly correlated with weight, lean 
body mass, height and age of the patients. In AO patients, IGF-I and IGFBP-3 
values did not correlate as strongly as in CO and their correlations with height, 
weight and lean body mass were less significant. Moreover, there was no correlation 
with age but only with GHD duration. It would seem that in AO patients the 
regulation of IGF-I and IGFBP-3 is different to that in CO. It follows that IGF-I, and 
certainly IGFBP-3, cannot be used in a straightforward manner for the diagnosis of 
adult onset GHD as established in pediatric patients. 
Anthropometric and body composition measurements describe the clinical 
presentation of the adult GHD syndrome and of its deviation from normal, but also 
provide additional distinguishing features between the two types of onset. The major 
difference in the clinical presentation relates to height. About 50% of CO GHD 
adults had a final height which was 2 or more SD below the average of a normal 
adult population despite hGH treatment during childhood and adolescence. 
One consequence of GHD is the accumulation of fat and obesity and in AO subjects 
this can be easily documented and quantified. Body weight, BMI, and waisUhip ratio 
compared to adult reference standards clearly demonstrated the high degree of 
obesity and its central (abdominal) accumulation. Although objective anthropometric 
evaluation is more difficult in CO subjects since adult reference standards do not 
correct for height, and pediatric reference standards do not correct for age and 
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maturation, it appears that these patients also were overweight. In fact the relative 
amount of body fat was virtually the same in both AO and CO, either measured by 
BIA or derived from skinfold thickness. However, AO patients had a significantly 
higher waisUhip ratio than CO which indicates that the distribution of body fat was 
not the same in the two groups, CO having less central fat accumulation than AO. 
In absolute terms CO subjects had significantly less lean body mass than AO. 
Correction of lean body mass for height (g/cm) separates CO from AO patients even 
better. While in AO subjects the amount of lean body mass appeared to be 
appropriate for their height, this was not the case in CO. In spite of the fact that CO 
patients were younger than AO patients, their very low value for LBM/height 
indicates that they may not have attained adult muscle mass. 
The smaller height, the decreased lean body mass and the amount and distribution 
of obesity of the CO GHD adult patients described indicate that the majority of them 
retained the full features of the clinical entity of hypopituitary dwarfism and in 
comparison to AO subjects they were somatically underdeveloped. It should be 
pointed out that the majority of our CO patients belong to a cohort of patients which 
had been treated with pituitary derived hGH, and hence could not benefit from the 
optimized therapy with biosynthetic hGH. Final height results in GHD children after 
hGH therapy have constantly improved since the advent of recombinant hGH, and a 
younger cohort of CO subjects may well have attained a better degree of somatic 
development than the patients of the present study (42). However, as a rule hGH 
therapy is being terminated with epiphyseal closure, and therefore the further steps 
to attain full somatic maturation, dependent upon the anabolic action of hGH, are 
not induced and completed. 
The lipid values in our GHD adults confirm a considerable prevalence of a mild 
degree of hypercholesterolemia and lowered HDL-cholesterol levels. The mean 
baseline cholesterol levels for each group were slightly elevated above the mean 
normal values, while the difference in total cholesterol between CO and AO 
individuals could be attributed to group age differences. Lowered HDL cholesterol 
concentrations are considered to be an important risk-factor for atherosclerosis and 
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an increased incidence of premature atherosclerosis (43), as well as an increased 
mortality from cardiovascular causes have been reported in hypopituitary patients 
(8). This may be particularly important in idiopathic GHD where left ventricular mass 
has been shown to be reduced (44) although in patients who acquire GHD as adults 
ventricular mass was normal (45). The clustering of several metabolic risk factors for 
cardiovascular diseases in a single subject has been studied (46). These risk 
factors include lowered HDL-cholesterol, raised insulin, and raised triglyceride 
levels, as well as obesity, increased abdominal fat and hypertension. In the present 
study AO subjects exhibited clear correlations between HDL cholesterol levels and 
body weight, 8MI, and waisUhip ratio, as well as between fasting serum insulin 
concentrations and weight, fat mass and waisUhip ratio. These correlations were 
much weaker or even absent in CO. The data do not support the concept that the 
same clustering of risk factors which has been referred to as syndrome X (46), the 
deadly quartet (47), or the insulin resistance syndrome (48) might exist in untreated 
GHD adults. Apart from the fact that no hypertensive patients were included in this 
study, very few of them had elevated fasting insulin levels or hypertriglyceridemia. 
We think that the abnormalities described are a genuine expression of the missing 
action of GH and are typically found in AO subjects in which GH withdrawal causes 
an acute imbalance of a previously normal metabolic control. In line with this, in CO 
subjects these abnormalities are much less pronounced, as these patients have 
adapted their metabolic control to GH deficiency during development. 
Quality of life as assessed by the Nottingham Health Profile also demonstrated 
differences in the presentation of the adult GHD syndrome between CO and AO 
subjects. Like all generic measures the NHP contains items which might not be 
relevant to the specific health problems of adult GHD patients, and therefore may 
lack sensitivity (49,50). However, it was the only available questionnaire validated in 
the different countries participating into the study, it contained quality of life 
dimensions related to the biological effects of GH (e.g. physical mobility), and it has 
been used previously in the evaluation of GHD patients (49-52). The NHP scores in 
the present group of 173 GHD individuals demonstrated that these patients were 
under severe distress. This is documented in Figure 4 where the NHP scores of the 
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GHD patients are compared to the scores from patients with a number of other 
diseases. 
The scores for the AO group were higher than those for CO in most dimensions, and 
the differences were statistically significant for physical mobility and energy level. 
This confirms the findings of Hunt et al (53) obtained from interviews with GHD 
patients, as well as other published data {51 ,52). It seems that most CO GHD 
patients have continuously adapted their lifestyle during growth and maturation to 
allow for their deficiency. In contrast, in AO patients the illness causing GHD has 
acutely affected a previously normal adult lifestyle. In line with the NHP findings, the 
HAD scale, which rates anxiety and depression, indicated a difference in these 
psychiatric variables between CO and AO GHD patients. 
In conclusion, adult onset and childhood onset GHD are two separate entities. The 
CO GHD syndrome is a developmental disorder; the clinical and biochemical 
findings indicate that they could not achieve full somatic maturation and suggest that 
their lifespan might be shortened by this missing stage. Unlike the CO GHD 
syndrome, the AO GHD syndrome is a metabolic disorder. The patients, who 
previously have gone through a developmental lifetime of normal GH secretion and 
attained complete physical maturation are upset by the withdrawal of normal 
endogenous GH secretion which produces a metabolic imbalance and their QoL is 
affected. 
When treating adult hypopituitary patients with hGH (and other necessary 
hormones) these differences between AO and CO should be kept in mind because 
the goal of therapy is different: induce and maintain full somatic development in CO 
patients, and restore normal QoL and prevent metabolic complications in AO 
patients. 
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3 The Effects of Human Growth Honnone (GH) Administration in GH· 
Deficient Adults: A 20·Day Metabolic Ward Study 
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ABSTRACT 
The early effects of human GH administration in GH-deficient (GHD) adults on protein, 
electrolyte homeostasis and body composition were investigated in a metabolic ward 
study. 
Four patients were studied. In addition to a constant caloric and nitrogen sufficient diet, 
the patients received GH for 15 days in dosages of 12.5-25 [lg/kg.day with a maximum 
of 1.48 mg (4 IU)!day. GH replacement therapy was well tolerated by all patients. There 
was a slowly increasing effect on IGF-I levels, which reached a maximum after 8-12 
days. The lowered IGFBP-3 levels normalized quicker, reaching maximum circulating 
concentrations 3 days after the start of GH treatment. Insulin concentrations maximally 
increased after 5 days, after which they leveled off. Insulin-like growth factor-binding 
protein-1 levels were maximally suppressed after 2 days of treatment. 
Nitrogen balance became positive in all patients (mean +2.8 ± 0.2 g! day). Maximal 
nitrogen retention occurred after 2-5 days of GH administration, after which adaptation 
occurred. This degree of nitrogen retention represents a formation of 20 g muscle! day, 
which would mean an increase of 3.6 kg muscle over a period of 6 months of GH 
replacement therapy. A rapidly occurring positive sodium balance was observed within 
24-72 h. Maximal sodium retention amounted to 61 mmol! day. It slowly decreased 
spontaneously over the subsequent 12 days. In parallel rapid changes in bioelectrical 
impedance analysis (BIA) were observed. There was a close parallel between the net 
cumulative sodium retention and the decrease in BIA in these patients during the first 15 
days of GH therapy. This suggests that the calculation of body composition 
compartments on the basis of BIA measurements during the initial phase of GH 
replacement does not represent actual changes in fat mass. This was substantiated with 
measurements of body composition using dual energy x-ray absorptiometry . 
In conclusion, measurements of early metabolic changes in GHD adults during the first 
15 days after the start of GH replacement indicate that IGF-I values reach maximal 
levels only after 8-12 days, that the measurements of changes in IGFBP-1 and IGFBP-3 
levels probably do not contribute to a determination of the optimal GH replacement 
dose, that maximal nitrogen retaining effects occur within 2-5 days after which 
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adaptation occurs, that massive sodium retention occurs during this period which 
spontaneously levels off and that cumulative sodium retention closely correlates during 
this period with changes in BIA. This suggests that measurements of body composition 
in patients with GHD by BIA should be interpreted with caution, 
INTRODUCTION 
GH has been available for the treatment of children with short stature for more than 30 
yr. (1), Lately it has also been used in clinical studies in GH-deficient (GHD) adults (2-5), 
Information concerning the early metabolic effects of replacement therapy with GH in 
GHD adults as well as on the course of the subsequent changes in body composition is 
limited, GHD adults have more body fat and less lean body mass than age-, sex-, 
height- and weight- matched controls (2-5), In hypopituitary dwarfs GH reduced the 
amount of subcutaneous (sc,) fat (6), whereas a reduction in both sc, and visceral 
adipose tissue was demonstrated during GH replacement in GHD adults (5,7), In a 
study of eight hypopituitary dwarfs an increase in muscle mass and a decrease in total 
body fat were recorded (8), These changes were also observed in GHD adults 
(4,5,7,9-12), 
The most common side effects of growth hormone replacement therapy are transient 
fluid retention, arthralgia and discomfort in muscles and occasionally the occurrence of 
carpal tunnel syndrome (5,7), Some of these symptoms seem to be related to sodium 
retention caused by GH administration (13,14), Evidence has also been presented that 
body composition measurements using bioelectrical impedance analysis (BIA) may 
result in an overestimation of the lipolytic effects of GH replacement therapy (4,13-15), 
GH exerts a positive effect on whole body nitrogen economy after operation (16), We 
found a decrease in nitrogen excretion after GH administration to catabolic elderly 
adults (17), Also during GH replacement therapy of GHD a net increase in protein 
synthesis using L-1-13C-leucine and 15N-glycine was found (4,18), The initial effects of 
GH replacement therapy on nitrogen balance in GHD adults have not been studied so 
far under metabolic ward conditions, 
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During GH replacement therapy of GHD adults, normalization of lowered insulin-like 
growth factor (IGF-I) levels was reported (2,3,5,7). Also the lowered IGF-binding protein-
3 (IGFBP-3) concentrations normalize during GH administration in GHD patients 
(19,20). Long term GH replacement therapy causes a moderate deterioration of glucose 
tolerance, which is accompanied by an increase in insulin secretion (18), eventually 
followed by a decrease in circulating IGFBP-1 levels (21,22). 
In the present study we investigated, under metabolic ward conditions the effects of GH 
replacement therapy in four GHD adults. During the first 15 days of GH administration 
the dynamics of the changes in circulating IGF-I, IGFBP-3, insulin and IGFBP-1 levels 
were monitored. Also the changes in nitrogen balance were measured. In addition the 
changes in sodium balance early after the start of GH replacement therapy are reported 
in relation to the rapid changes in bioelectrical impedance. 
MATERIALS AND METHODS 
Patients 
Four patients with long-standing GHD were studied (Table 1). In all four patients GHD 
was confirmed by decreased circulating IGF-I concentrations and an insufficient rise of 
GH levels after iv GHRH administration. None of these patients suffered from renal or 
liver disease or diabetes mellitus, or had a history of cancer. One patient (no. 4) had 
osteogenesis imperfecta. 
TABLE 1. Clinical and biochemical characteristics of the four ~atients included in the stud~ 
Case Age Ht WI Sex Cause of pituitary Diagnosisa PeakGH 
no. (yr) (em) (kg) deficiency (mglL)b 
35 181 96 m Cranlopharyngeoma TAGDI 2.3 
2 49 138 69 Idiopathic TAG 1.7 
3 35 165 96 Craniopharyngeoma TAG 1.1 
4 37 162 52 m Congenital TAG 4.2 
a Tt thyroid deficiency; A, adrenal deficiency; G, gonadal deficiency; 01, diabetes insipidus. 
b Peak GH, maximal GH level after iv injection of GHRH (1 )lg/kg BW). 
e Normal range. 12,0·49.8 nmollL. 
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Protocol 
The patients were admitted to the Clinical Research Unit for a period of 23 days. During 
the entire study they were given the same diet every day. The diets were prepared in 
accordance with the wishes of the patients, weighed and frozen before hospital 
admission. The patient's own account and visual confirmation by the nursing staff were 
used to check completeness of food intake. Two diets were diluted with distilled water 
and homogenized for measurements of the nitrogen and mineral contents. 
The first 3 days after admission were used to achieve metabolic balance (these are not 
included in the figures). In the next 5 days, pretreatment measurements were made (-4,-
3,-2,-1 and 0). From day 0 onward, the patients received recombinant derived human 
GH. The patients injected themselves daily sc. at bedtime. Patients 1, 3 and 4 received 
251Ig/kg.day with a maximum of 1.48 mg (4 IU)/day. Patient 2 received only half this 
dose (12.5 Ilg/kg.day). This lower dose was given because this patient already 
spontaneously complained of signs and symptoms of fiuid retention. rhGH (Humatrope) 
was supplied by Eli Lilly Co. (Indianapolis, IN). 
At 0800 h, weight, temperature, blood pressure, pulse rate and impedance were 
measured. Also fasting blood samples were taken for glucose, IGF-I, IGFBP-3, insulin 
and IGFBP-1 assessments. At regular intervals routine hematological and clinical 
chemical parameters were determined. Urine was collected in 24-h samptes. In each 
sample, nitrogen, creatinine, sodium (Na), potassium, and glucose were measured 
quantitatively and ketone bodies were determined qualitatively. 
Stools were collected in 4-day periods from day -4 onward. The 4-day periods were 
demarcated by the administration of 1200 mg polyethylene glycol every fourth day. 
Fecal nitrogen and Na were measured in each pooled sample after homogenization. 
The aims and methods of the study were explained to the patients and written informed 
consent was obtained before the study, which was approved by the ethics committee of 
the University Hospital Dijkzigt (Rotterdam, The Netherlands). 
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Methods 
Routine methods were used for the hematological and chemical measurements in 
blood. Urinary, fecal and dietary nitrogen levels were determined with the use of an 
automatic nitrogen analyzer (type 1400, Carlo Erba, Milan, Italy). The electrolytes were 
determined by flame photometry. Fecal polyethylene glycol was measured by a 
turbimetric method. Nitrogen balance was calculated by subtracting urinary, fecal and 
integumental nitrogen excretion from the dietary intake. Integumental nitrogen loss was 
estimated to be 0.5 g/day (23). 
Total IGF-I levels were determined by RIA, using kits obtained from Medgenix 
Diagnostics (Brussels, Belgium; intra-assay coefficient of variation (CV), 4.1-6.1 %; 
interassay CV 9.3-9.9%]. Insulin levels were determined by immunoradiometric assay 
(IRMA) using kits obtained from Medgenix Diagnostics (Brussels, Belgium, intraassay 
CV, 2.1-4.5%; interassay CV, 4.7-12.2%). IGFBP-1 levels were determined by IRMA 
(Diagnostic Systems Laboratories, Webster, TX; intraassay CV, 3.4-6.0%; interassay 
CV, 1.0-3.5%). IGFBP-3 levels were determined by IRMA (Diagnostic Systems 
Laboratories; intraassay CV, 0.56-3.90%; interassay CV, 0.49-1.9%). Normal values for 
these four parameters are shown in Tables 2, A and B. 
Body composition 
Body composition was measured by BIA and dual energy x-ray absorptiometry (DXA). 
Estimation of lean body mass, total body water, and fat mass was performed using a 
tetrapolar bioelectrical impedance analyzer (model BIA 101, RJL Systems, Detroit, MI). 
The principle of the BIA is that lean tissues, comprised largely of electrolyte containing 
water, readily conducts an applied current (of 800 ftA at a signal frequency of 50 kHz) 
which is generated by a bioelectrical impedance analyzer, whereas fat conducts little 
current. After correct positioning of the patients and the electrodes and assuming that 
the two compartments act in parallel, the impedance of the body is controlled by the low 
impedance lean compartment and is a function of the specific resistance of lean tissue, 
the cross-sectional area and the length of the lean compartment. As water is the major 
component of the lean body compartment, total body water can be calculated from the 
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measured impedance (24-27). Fat free mass was calculated using the equation of 
Lukaski (25). 
DXA is a noninvasive method of measuring bone and soft tissue body composition. DXA 
directly measures fat mass, lean tissue mass and total body bone mineral content. The 
reported CVs are 6.6%, 1.5% and 0.5% respectively (28). Body composition was 
determined by scanning each subject on a Lunar DPX Bone Densitometer (Lunar, 
Madison, WI). This equipment uses an x-ray source which produces a dual energy 
beam with energies of 38 and 70 kiloelectron volts by K-edge filtering using cerium. The 
DPX system performs rectilinear scans over the entire length of the patient's body, 
beginning at the top of the head and moving downward toward the feet. A total body 
scan takes approximately 15 min. and the subject receives less than 0.5 microSievert 
radiation exposure. The analysis software calculates fat mass, lean tissue mass and 
bone mineral content (29). 
The statistical significance of the differences between mean values was determined 
using one-way analysis of variance. When significant overall effects were obtained by 
analysis of variance, multiple comparisons were made with the Newman-Keuls test. All 
data are shown as the mean ± SEM. P < 0.05 was considered significant. 
RESULTS 
The administration of GH was well tolerated by all four patients. None of them 
complained of signs or symptoms related to water retention. 
The circulating IGF-I and IGFBP-3 levels increased in all patients during GH therapy 
(Table 2A). The course of this increase was variable: maximal levels were reached after 
8-12 days of GH treatment in the three patients who were treated with 25 fl9/kg.day of 
GH. In patient 2, who only received 12.5 It9 GHlkg.day, IGF-I levels increased from 2.2 
nmollL to a maximum of 11.3 nmollL (Fig. 1). IGFBP-3 levels were decreased in all four 
patients before the start of GH replacement and increased 2- to 5-fold in the subsequent 
period. The maximum increase in IGFBP-3 levels was reached after 3 days of GH 
replacement therapy when IGF-I levels were still rising (Fig. 2A). The relationship 
between IGF-I and IGFBP-3 levels in all four patients during the first 15 days of GH 
replacement therapy is shown in Fig. 3 (calculated linear regression: r=0.83; P < 0.05). 
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TABLE 2A. Overnight fasting levels of IGF-I and IGFBP-3 
Patient no. GH daily IGF-I (nmol/l) IGFBP-3 (mg/l) 
dose (~lg) 
pretreatment day 15 pretreatment day 15 
1480 2.7 58.3 0.84 3.64 
2 740 2.2 9.8 0.31 1.33 
3 1480 6.2 35.1 1.79 3.42 
4 1288 10.0 67.7 1.48 3.02 
mean ±SEM 5.3 ± 1.8 42.7 ± 12.9' 1.10±0.33 2.85 ± 0.52' 
normal range 12.0·49.8 2.09-3.63 
iI P < 0.05 vs. pretreatment. 
TABLE 2B. Overnight fasting levels of insulin, IGFBP·1 and glucose 
Patient no. Insulin (mUll) IGFBP-1 (mg/l) glucose (mmoIlL) 
pretf day 15 pretf day 15 pretf day 15 
9.1 31.7 3.7 0.3 3.5 3.9 
2 10.7 17.7 12.0 9.1 3.4 4.1 
3 11.6 12.0 4.9 0.7 5.6 5.4 
4 4.4 7.5 72.6 5.8 3.4 4.7 
mean ± SEM 8.9±1.6 17.2±5.3 23.3±16.5 4.0±2.1 4.0±0.5 4.5±0.3 
normal range 2.0-25.0 10-150 3.3·6.0 
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Fig.1 The course of the IGF·I levels during the study period In the four Individual GHD patients. GH 
replacement therapy was initiated on the evening of day zero. Five pretreatment measurements 
were eanied out. 
Insulin levels increased during GH replacement therapy. The initial maximal increase in 
insulin levels 3-5 days after the start of GH replacement therapy tended to decrease in 
the subsequent 10 days (Fig. 2B). During this period, no glucosuria was found, whereas 
fasting and postprandial glucose levels did not change significantly (see also Table 2B). 
IGFBP-1 levels sharply decreased within 2 days after the start of GH replacement 
therapy and remained constant thereafter (Fig. 2B). During the first 5 days of GH 
administration there was a marginal negative correlation between the circulating insulin 
and IGFBP-1 levels (r~-0.40, P = 0.056). 
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Fig. 3 The relationship between the changes in circulating IGF-I levels during GH replacement therapy. 
(calculated linear regression: r = 0,83; P< 0,05) 
Nitrogen balance became positive in all four palients direclly after the start of GH 
replacement therapy (Fig. 4A). Nitrogen retention was maximal from the second day 
onward, with a maximum of 3.8 g/day after two injections on day 2 (Fig. 4A). Statistical 
analysis showed that nitrogen balance was positive compared to pretreatment values 
only on days 2-5 after the start of GH administration (P < 0.05 vs. control). Thereafter, 
no statistically significant changes occurred, which suggests an early adaptation of the 
nitrogen-retaining effects of GH administration from day 6 onward. The mean retention 
of nitrogen from days 1-15 after the start of GH administration amounted to 2.8 ± 0.2 
g/day. Interestingly, in patient 2, who received 50% of the GH dose, which led to a 
subnormal increase in IGF-Ilevels, nitrogen retention was similar to that observed in the 
other three palients (2.7 ± 0.5 vs. 2.8 ± 0.5 g/day). 
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From the start of GH administration an early and considerable retention of sodium was 
obseNed in all patients (Fig. 4B). This was not accompanied by a change in body 
weight in three patients, whereas patient 4 showed an increase in body weight of 1.8 kg. 
During the course of the 15 days of GH administration, sodium balance tended to 
reverse spontaneously. Sodium retention on day 2 of GH administration was to 61 ± 16 
mmollday vs. the control value of 12 ± 16 mmo[/day (P < 0.05). On day 15 of GH 
administration sodium retention was 28 ± 24 mmo[/day (P = NS vs. control). Potassium 
balance was positive in all four patients. There was a maximum retention of 22 ± 4 mmol 
on the third day of GH administration. This did not reach statistical significance because 
there was already modest potassium retention in the pretreatment period (8 ± 3 
mmo[/day). The pattern of the course of potassium balance was similar to that of sodium 
(data not shown). 
No changes in kidney or liver function tests, electrolytes, cholesterol, trig[ycerides, tota[ 
protein and albumin or leukocyte count were found. 
Before GH administration, body composition was measured by B[A and DXA. [n table 3, 
the course of B[A measurements before treatment and on days 3-6 and on 12-15 of 
treatment are shown together with the ca[culated fat mass and fat free mass on these 
days. The DXA measurements were performed before treatment and on day 15 of 
treatment (Table 3). According to the calcu[ations by BIA, rapid changes were obseNed 
in the fat free mass as well as the absolute fat mass by 3-6 days after the start of GH 
administration. After 12-15 days of GH administration there was a decrease in fat 
percentage as measured by BIA, from a mean of 44.6% to 36.0%. The corresponding 
change measured by DXA amounted only to a decrease from 32.8% to 30.7%. In Fig. 5, 
the relationship between the course of cumulative sodium retention and the absolute 
values of bioelectrical impedance values during GH administration in a[1 four patients is 
shown. Interestingly, there was a close correlation between cumulative sodium retention 
and the changes in bioe[ectrical impedance during GH administration (r = -0.93; P < 
0.0001 in Fig. 5). 
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replacement therapy. There was a statistical significance between both parameters. 
(r = -0.92, P<O.OO5). 
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Table 3. Body composition measurements by BIA and DXA in the four patients. 
Patient Before treatment Mean days 3--6 Mean days 12-15 
no. R FFM FM FAT R FFM FM R FFM FM FAT 
(ohm) (kg) (kg) (%) (ohm) (kg) (kg) (ohm) (kg) (kg) (%) 
BIA 
1 537±12 55.3±1.2 41.1±1.4 42.6 509±8 58.2±0.8 36.2±0.4 462±11 63.8±1.5 33.1±1.5 34.2 
2 621±1 29.7±0.0 38.7±0.0 56.6 570±8 32.0±0.4 36.9±0.4 550±13 33.1±0.7 36.1±0.6 52.2 
3 477±9 52.0±0.9 43.9±1.0 45.8 473±10 52.6±1.1 42.8±1.0 450±9 55.0±1.1 38.3±0.9 41.1 
4 729±12 34.1±0.5 17.1±0.4 33.4 632±4 38.8±0.2 14.0±0.1 530±15 45.6±1.2 9.2±1.0 16.8 
DXA 
1 67.7 25.8 27.6 72.0 22.5 23.8 
2 34.4 33.1 49.1 35.1 32.7 48.2 
3 55.6 37.3 40.2 56.3 34.0 37.7 
4 43.9 7.3 14.3 47.7 7.2 13.1 
The BIA measurements before as well as 3-6 and 12-15 days after GH administration are the mean ± SEM of four determinations. 
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DISCUSSION 
In this study we investigated under metabolic ward conditions the course of the early 
effects of GH replacement therapy in GHD adults. Before the start of treatment IGF-I 
and IGFBP-3 levels were decreased in all patienls. GH administration resulted in a rapid 
rise in IGFBP-3 levels, which seemed to be independent of the changes in circulating 
IGF-I concentrations. Maximal (normalized) IGFBP-3 levels were found after 3 days of 
GH therapy. This means that the measurement of IGFBP-3 levels, which has been 
suggested to be of value in the diagnosis of GH deficiency in adulthood (30-32), 
probably has limited value in determining the optimal dose of GH for replacement 
therapy in individual patients. Also the course of changes in IGF-I levels, as observed 
during the first 15 days of GH replacement therapy casts doubts on its value as a 
parameter to be used in determining the optimal dose of GH. This assumption is 
substantiated by the observation that nitrogen retention was already maximal from day 2 
of GH administration, whereas circulating IGF-Ilevels had only just started to increase. 
In patient 2 who was treated with a low dose of 12.5 f'9 GHlkg.day, IGF-I levels did not 
normalize, whereas the degree of nitrogen retention, changes in sodium balance, as 
well as changes in body composition during the first 15 days of GH therapy were similar 
to those observed in the three patients who were treated with a double dose of GH, 
eventually resulting, after 8-15 days in a normalization of circulating IGF-I levels. Also 
the changes in IGFBP-1 levels were confirmed to be mainly dependent on the changes 
in insulin levels and the measurement of IGFBP-1 levels does not contribute to our 
understanding of the dynamic changes in IGF-I bioactivity, as maximal suppression of 
IGFBP-1 concentrations was reached within 2 days after the start of GH replacement 
therapy. 
Our studies on the effects of GH replacement therapy on nitrogen balance confirm 
previous observations in GHD children (33). A remarkably rapid nitrogen-retaining 
effect, with a maximum reached after 2 days, was observed. Also, interestingly, this 
positive effect of GH seemed, under these metabolic ward conditions, in which nitrogen 
intake was standardized, to level off after 5 days. Whole body studies on nitrogen 
retention reflect total protein synthesis which represents the net effect of potentially 
antagonizing changes involving both protein synthesis as well as breakdown (34). 
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Earlier studies in postoperative patients receiving various nutritional regimens showed 
that short term (7 days) GH administration increased nitrogen turnover and synthesis, 
whereas degradation either increased or remained unchanged (35). In obese patients 
receiving hypocaloric nutrition, the N-retaining effect of GH appeared to wear off after 3-
5 weeks (36). Our own previous studies on the effect of GH replacement in GHD adults 
with 15N-glycine incorporation measurements also demonstrated an increased (initial) 
rise of protein synthesis, followed by a higher rate of protein degradation (4). 
During GH treatment for 6 months significant increases were noted in the cross-
sectional area of thigh and quadriceps muscle which correlated with the changes in lean 
body mass measured with -10K (34). We observed in our patients a mean nitrogen 
retention of 2.8 g/day during the first 15 days of GH replacement therapy. This accounts 
for approximately 17 g of whole body protein synthesis, which represents 20 g of muscle 
(34,37,38). In 2 weeks, an estimated mean increase in muscle mass of 300 g is to be 
expected, which over a 6-month period would lead to an increase in total muscle mass 
of 3.6 kg. This indeed is in the range of the changes that have been reported during GH 
replacement therapy in GHD adults in several studies (3,5,9). 
BIA determines the percentage of fat from total body water measurement (24). The 
accuracy of the percentage of body fat derived from this method depends on the 
hydration status of the body. Exercise-induced dehydration causes a decrease in the 
percentage of fat measured by BIA because of a decrease in total body weight, without 
a change in the fat free mass (39). Acute changes in the circulating volume in patients 
receiving hemodialysis cause a rapid change in resistance measured by BIA. Although 
no estimates of body composition were reported in these patients, these acute changes 
may also affect estimates of body composition (40). In GHD patients there is an 
increased resistance that cannot only be explained by their lower lean body mass. 
Resistance is determined by both the hydration state and the electrolyte content of the 
lean body mass (14). In our patients, body composition measurements by BIA showed 
rapid initial changes in fat mass and fat free mass shortly after the initiation of GH 
replacement therapy. These changes in BIA were demonstrated to be largely due to 
sodium and water retention, taking place soon after the start of therapy. The observed 
rapid decrease in total fat mass was overestimated by BIA. In a comparative study in 
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elderly subjects an accurate estimation of the amount of total body fat could be made by 
BIA and anthropometry depending on the regression equations used (41). This study 
also showed a considerable lack of agreement between body fat measured by DXA and 
body fat measured by BIA in several equations. There was an overestimation of body fat 
by most of the equations. The DXA method measures fat, bone mineral and lean tissue 
separately. In this it seems to have a greater precision than most of the other currently 
used methods (42). In our patients there was a decrease in fat percentage measured by 
BIA from 44.6% to 36.0%. With DXA there was a decrease only from 32.8% to 30.7%. 
This difference was shown to be mainly caused by overestimation of the decrease in fat 
mass by BIA. In conclusion, the changes in resistance reflected mainly the changes in 
the extracellular water composition. Therefore the resulls of this technique should be 
interpreted with great reserve in patients with GHD (14). 
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4 Combined Treatment of Growth Hormone (GH) and the Bisphosphonate 
Pamidronate vs. Treatment with GH Alone in GH·Deficient Adults: The 
Effects on Renal Phosphate Handling, Bone Turnover and Bone Mineral 
Mass 
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ABSTRACT 
A potential drawback of GH replacement therapy in GH deficient (GHO) patients is 
the initial decrease in bone mass. The present study investigates the effects of the 
addition of pamidronate to GH replacement therapy in adult GHO subjects, on serum 
levels of parathyroid hormone (PTH) and 1,25-dihydroxyvitamin 03 (1,25-(OH)203), 
renal phosphate handling, bone turnover and bone mineral content (BMC). 
Six GHO adult patients were studied for two periods of six months with a wash out 
period of three years. In the first period they were treated with conventional 
replacement therapy and GH. In the second study period GH treatment was 
identical, while after two weeks 150 mg pamidronate per day was added. 
In the first study period (GH only) there was a significant increase of phosphate 
reabsorption, without a change in serum PTH and 1,25-(OH)203 levels. This 
suggests a specific effect of GH or IGF-I on renal phosphate handling. This, indeed 
was supported by the close correlation between serum IGF-I levels and TmP/GFR 
(r=0.75, P<O.0001). When GH was administered together with pamidronate, this 
correlation was less, but remained significant (r=0.44, P<O.001). 
The increase in bone turnover and decrease in BMC, as initially observed during 
GH replacement therapy alone, were attenuated by simultaneous pamidronate 
administration. The percentual decline of lumbar spine BMC (measured with dual-
photon absorptiometry) at six months was -3.1 ± 1.5% during GH replacement 
therapy alone, versus +3.8 ±2.0% during the administration of the combination of 
GH and pamidronate (measured with dual-energy x-ray absorptiometry). At the 
distal and proximal forearm the changes amounted -0.5 ± 3.4% versus +4.5 ± 1.8% 
and -1 ± 1.2% versus +1.2 ± 1.1% respectively. 
In conclusion this study shows that the addition of a bisphosphonate to GH 
replacement therapy in GHO adults counteracts the GH (or IGF-I) induced increase 
in renal phosphate reabsorption. Furthermore, it reduces GH-induced bone turnover 
and prevents the initial decrease in bone mineral content as seen during GH 
treatment alone, resulting in a beneficial effect on bone mineral mass. Pamidronate 
might therefore be an important adjunct to GH replacement therapy in adults with 
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GHD and severe osteopenia during the early phase of GH-induced stimulation of 
bone turnover. 
INTRODUCTION 
Several studies indicate that GH increases renal phosphate reabsorption and 
stimulates the renal production of the active vitamin 0 metabolite 1,25-
dihydroxyvitamin 0 (1,25-(OH)2D3 (1,2). In other words at the level of renal 
phosphate handling GH appears to act as a parathyroid hormone (PTH) antagonist, 
while at the level of the renal 1 a-hydroxylase an opposite more PTH-like action 
appears to take place (3). This apparent dichotomy in the interaction between GH 
and PTH prompted us to compare two periods of GH replacement therapy in the 
same GH deficient (GHD) individuals; one period with GH treatment alone and a 
second period whereby GH treatment was combined with the bisphosphonate 
pamidronate. It is known from other studies that pamidronate treatment results in an 
increase of PTH levels (4-6). 
Recent reports also indicate a high prevalence of osteopenia in subjects with growth 
hormone deficiency (GHD) of both childhood (7,8) and adult onset (9,10). Other 
investigators showed an increased susceptibility for fractures in this group, which is 
compatible with the inverse relationship between bone mineral density (BMO) and 
fracture risk (11-13). Also a positive correlation between circulating insulin-like 
growth factor (IGF-I) and BMD in individuals with acquired GHO has been reported 
(14,15). Based on these observations clinical studies were initiated to establish the 
potential effects of GH replacement therapy on bone turnover and bone mass (16-
18). Several reports indicate that GH replacement results in a considerable increase 
of bone turnover as indicated by an increase of markers of bone resorption and 
bone formation (18-23). This increase in bone remodeling might result in an 
increase of remodeling space with a subsequent loss of bone mineral mass. This 
indeed was observed in a group of GHD adults we have followed on GH 
replacement therapy for six months (24). However, long-term treatment with GH up 
to 30 months leads, after an initial downwards trend, to a sustained increase of bone 
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mineral content (BMC) as measured in the axial and appendicular skeleton (25-28). 
In other words long-term GH replacement therapy appears to result in a favourable 
shift in the balance between bone resorption and bone formation. In the present 
study we investigated the effects of GH replacement therapy in a group of GHD 
patients in combination with an inhibitor of bone resorption, the bisphosphonate 
pamidronate. Given the fact that bone turnover is initiated with bone resorption, we 
added in the present study pamidronate two weeks after the initiation of GH 
replacement therapy. 
Taken together, the present study performed in GHD subjects compares the effects 
of GH alone and GH with pamidronate on parameters of renal phosphate handling, 
bone turnover and bone mineral mass. 
MATERIALS AND METHODS 
Patients 
Eight patients with long-standing GHD were treated with GH alone for six months 
(24). The baseline characteristics of the six patients who agreed to enter the second 
part of the study three years later are shown in Tables 1 and 2. 
TABLE 1. Clinical and biochemical characteristics of the six patients included in the study 
Case no. GH daily dose(~g) Sex Cause of pituitary deficiency Diagnosisa 
1480 m Craniopharyngeoma TAGDI 
2 740 Idiopathic TAG 
3 1480 Cranlopharyngeoma TAG 
4 1288 m Congenital TAG 
5 1110 Craniopharyngeoma G 
6 1480 m Cranlopharyngeoma 
a T, thyroid deficiency; A, adrenal deficiency; G, gonadal deficiency; 01, diabetes insipidus. 
b Peak GH, maximal GH level after Iv injection of GHRH (1 ~tg/kg 8W). 
PeakGH 
(mg/L)' 
2.3 
1.7 
1.1 
4.2 
2.9 
3.2 
Age of onset of GHD was between 13 and 19 years of age. Two patients received 
GH treatment during childhood (no. 4 and 6) more than 10 years earlier. In the first 
study period patients 1, 3 .4 and 6 received 25 jlg/kg.day with a maximum of 1.48 
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TABLE 2. Clinical and biochemical characteristics of the patients 
Characteristic GH (period I) GH + APD (period II) 
mean range mean range P 
Age (yr) 33.7 25-46 36.7 28-49 
Height (cm) 162.3 137-182 163.2 138-181 NS 
Weight (kg) 73.3 47-95 80.8 52-102 0.004 
BMI (kg/m2) 27.6 18.1-33.8 30.3 19.8-36.2 0.007 
Serum calcium (mmoIlL). 2.21 2.16-2.23 2.17 2.08-2.42 NS 
Serum phosphate (mmol/L) 1.19 1.11-1.28 1.10 0.98-1.22 NS 
1 ,25-(OH),D3 (pmol/L) 80 57-103 77 54-114 NS 
PTH (pg/mL) 20 13-32 26 15-32 0.017 
TmP/GFR (mmoIlL) 1.0 0.8-1.2 1.1 0.9-1.2 NS 
Apase (U/L) 71 39-150 58 37-97 NS 
Osteocalcin (fI9/L) 4.1 2.6-7.5 3.2 1.-8.0 NS 
Procollagen I (flg/L) 85.7 56-116 72 21-139 NS 
Urinary OH-proline 20.8 9.6-39.4 23.5 10.2-60.0 NS 
(mmollmol creat) 
BMC SPADIST (U/cm) 30.9 18.4-42.6 32.9 25.2-42.2 NS 
BMC SPApROX 33.8 22.3-44.5 34.7 25.5-44.9 NS 
NS: no significance between groups 
• serum calcium corrected for serum albumin. 
mg (4 U) per day. Patient 2 received only half this dose (12.5 flg/kg.day). This lower 
dose was given because this patient already spontaneously complained of signs 
and symptoms of fluid retention. Patient 5 received 18fI9/kg.day. She complained of 
fluid retention in the initial part of the study at which time the dose was reduced. 
Patients received GH replacement therapy for six months at the same dose in the 
two study periods. rhGH (Humatrope) was generously supplied by Eli Lilly Co., 
Indianapolis, IN .. In the second study period, from day 16 onward, the patients were 
cotreated with pamidronate 150 mg per day orally. Measurements were performed 
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at baseline, 1 month, 3 months and six months in the first study period and again at 
baseline, two weeks, 3 months and six months in the second study period. During 
and in between both treatment periods conventional pituitary replacement therapy 
remained unaltered. 
The aims and methods of the study were explained to the patients, and written 
informed consent was obtained before the study, which was approved by the ethics 
committee of the University Hospital Dijkzigt (Rotterdam, The Netherlands). 
Bone mass measurements 
Lumbar bone mass (lumbar vertebrae, L2-L4) was measured, during the first study 
period using Dual-Photon Absorptiometry (DPA, Novo BMC-Lab 22a scanner). In 
the second study period a Lunar DPX Bone Densitometer (Lunar Corp., Madison, 
WI) was used. The short-term coefficients of variation (CV) in normal subjects for 
DPA and DXA were 2.3% and 1.1 % respectively (29,30); in vivo correlation between 
both methods, as measured on the same day, was high (based on 252 lumbar spine 
measurements, r=0.984, P=1.29 ± 0.015, P < 0.001). The results are expressed as 
BMC (g hydroxyapatite (Hal). Quality assurance including calibration, was 
performed routinely every morning. No drift was observed during both study periods. 
Single-Photon Absorptiometry (SPA) of the right forearm was performed at the distal 
and proximal sites using a Nuclear Data 1100a scanner (31). The (fat-corrected) 
results are expressed as BMC (arbitrary units (U) per cm). The CV in our institution 
is 1.9% for the distal site and 1.0% for the proximal site (29). 
Measurements and laboratory tests 
Routine methods were used for the measurements of total alkaline phosphatase 
(APase) and inorganic phosphate (Pi). The renal tubular reabsorption maximum of 
phosphate corrected for glomerular filtration rate (TmP/GFR) was calculated 
according to Bijvoet (32). Serum osteocalcin and the carboxy terminal pro peptide of 
type I collagen (PICP) were determined by commercially available kits (INCSTAR 
Corp., Stillwater, MN and Orion Diagnostica, Espoo, Finland respectively). 
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24-hour Urinary excretion of hydroxyproline (Organon Technika, Oss, The 
Netherlands) expressed as mmol OH-proline per mol creatinine was assessed at 
each visit. Prior to urine collections patients were on a gelatin free diet for three 
days. 
25-hydroxyvitamin D3 (25-(OH)D3), 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) and 
intact PTH (1-84) were determined using commercially available kits (INCSTAR 
Corp., Stillwater, MN). 
Statistical analysis 
Paired T -tests were performed to analyze the effects on renal phosphate handling, 
bone turnover parameters and BMC between the two periods as well as within the 
two study periods. Results are expressed as mean ± SEM. P < 0.05 was considered 
significant. 
RESULTS 
All patients gained weight during the three year interval. Since height did not 
change, this also resulted in a Significant increase of BMI (Table 1). PTH levels 
were significantly different at the beginning of the two study periods. Although none 
of the other parameters differed significantly, there was a tendency to a somewhat 
lower bone turnover and higher BMC at the beginning of the second study period 
(Table 2). 
GH replacement therapy was well tolerated. In the second study period, one patient 
was treated with furosemide 20 mg for two weeks in the third and fourth week of GH 
therapy because of tense feeling in the fingers due to mild edema. Also in the 
second study period two of the six patients complained of gastrointestinal discomfort 
after the initiation of pamidronate. This disappeared spontaneously within two 
weeks. 
The rise of IGF-I levels in the second study period was similar to that reported for 
the first study period (24). 
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Biochemical measurements 
Despite the higher baseline serum PTH 
levels during combined treatment, the 
rise of PTH levels was more prominent 
than during treatment with GH alone 
(Fig. 1 A). The increase of PTH levels 
was significantly higher on combined 
treatment (P < 0.05). A similar trend was 
observed for 1,25-(OH)2D3 levels, 
although no significant difference 
between treatment periods could be 
observed (Fig. 1 B) . 
25-(OH)D3 levels did not change in 
either treatment period (results not 
shown). Serum phosphate increased 
from 1.19 ± 0.03 to 1.48 ± 0.03 mmoliL 
in the first study period and from 1.10 ± 
0.03 to 1.35 ± 0.03 mmol/L in the second 
study period (P < 0.05 baseline vs. six 
months). TmP/GFR increased in both 
treatment periods, with a less prominent 
rise during combined treatment, 
reaching significance at three months 
(Fig. 1 C). Although the correlation 
between serum IGF-I and TmP/GFR was 
highly significant (P < 0.001) during both 
treatment periods, addition of 
pamidronate weakened this relationship 
(r=0.75 vs. r=0.44) (Fig. 2). 
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In both treatment periods an increase in markers of bone formation (ic. osteocalcin, 
APase and PICP) was observed. However, versus baseline the increase of the 
biochemical markers of bone turnover was markedly blunted in the second study 
period from the moment that GH replacement therapy was combined with 
pamidronate (Fig. 3A-C). 
Urinary hydroxyproline as a measure of bone resorption rose significantly in both 
treatment periods. It reached a maximum after 1 month during treatment with GH 
alone, whereas an attenuated response was observed after addition of pamidronate 
(Fig. 3~). 
24-hour Urinary calcium excretion increased significantly, but was not significantly 
different between the two periods (data not shown). 
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Bone mineral content 
The baseline date for bone mineral mass are shown in Table 1. The changes of the 
bone mass measurements during the two treatment periods are shown in Fig. 4. 
Only BMC data are shown, because bone mineral density data showed similar 
changes. 
Lumbar spine. In the first treatment period there was a significant decrease in BMC 
after three and six months of GH replacement therapy (-1.5 ± 1.3% and -3.1 ± 1.5%, 
respectively). In the second treatment period there was an increase in BMC, which 
already reached significance versus baseline at six months (3.8 ± 2.0%). The 
difference between the periods was already nearly significant at three months and 
reached significance at six months (P=O.052 and P=O.04 respectively) 
Distal forearm. In the first treatment period there was a significant decrease in BMC 
as measured in the distal forearm at three months. At six months BMC was still 
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DISCUSSION 
lower vs. baseline, however not 
significantly (-4.8 ± 2.0% and -0.5 
± 3.4%). In the second treatment 
period there was an increase at 
three and six months (2.5 ± 0.7% 
and 4.5 ±1.8'10). The difference 
between the periods was 
significantly different at three 
months, but not at six months of 
therapy (P=O.036 and P=O.239 
respectively). 
Proximal forearm. The initial 
decline in BMC in the first 
treatment period was significantly 
greater than in the second 
treatment period. After six months 
in the second treatment period 
BMC levels were above baseline 
(-1.4 ± 0.6% and -1 ± 1.2% in the 
first period versus -0.3 ± 0.4% 
and 1.2 ± 1.1% at three and six 
months, respectively). Changes 
were not significantly different 
between periods. 
Our study indicates that addition of pamidronate to GH replacement therapy in GHD 
adults attenuates the GH-induced increase of the renal phosphate threshold and 
prevents the initial bone loss as observed during treatment with rhGH alone. 
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As observed during the first study period GH induced a pronounced increase in 
renal phosphate reabsorption. This increase was not accompanied by changes of 
the phosphate regulating hormones PTH and 1,25-(OH)2D3. Therefore, a direct 
effect of GH or IGF-I on renal phosphate handling is more likely, which is also 
supported by the high correlation observed between IGF-I and TmP/GFR Also 
recent in vivo and in vitro studies (33,34) suggest a similar mode of action. That GH 
does not affect the PTH-induced phosphaturic response is provided by the 
observation that the rise of PTH levels, as observed after the addition of 
pamidronate, is accompanied by a lowering of the renal phosphate threshold. In 
other words it appears that the GH-induced increase in phosphate reabsorption is 
counteracted by a PTH-induced decrease. Based on these observations it is unlikely 
that GH at the level of renal phosphate handling acts as a PTH-antagonist (3). 
Recent studies also indicate that GH or IGF-I stimulates renal 1et-hydroxylase 
activity (3). In the first study period we did not observe a significant rise of 1,25-
(OH)2D3 levels, which might be explained by the prominent increase of serum 
phosphate levels during GH treatment It is known that hyperphosphatemia is a 
potent inhibitor of 1et-hydroxylase activity (35). The lower phosphatemic response 
after addition of pamidronate might, therefore, explain the trend towards higher 
1,25-(OH)2D3 levels during the second study period. Of course, it is also possible 
that this represents a direct effect of the raised PTH levels on the renal 1 a.-hy-
droxylase. 
When we compare the pretreatment values of biochemical markers of bone turnover 
and bone mass between both study periods, there appears to be a tendency to a 
somewhat lower bone turnover and a somewhat higher BMC at the start of the 
second study period. Nevertheless, the differences in these markers did not reach 
significance, which exclude an important "carry-over" effect of GH treatment from 
the first to the second study period. The somewhat higher bone mass at the start of 
the second study period could be related to the increase in body weight between 
both study period. Several studies have shown a positive relationship between body 
weight and bone mineral measurements. 
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As shown by the results obtained during the first study period GH leads to an 
increase in bone turnover. During an initial phase the GH-induced increase in the 
number of activated bone remodeling units will result in a larger bone surface 
undergoing bone resorption and subsequently will result in bone loss. An initial 
decrease in BMC was indeed found during treatment with GH alone in our patients, 
as well as by others (26). During a second phase the coupling between bone 
resorption and formation will result in a new balance, which will limit bone loss (32). 
However, Vandeweghe et al observed that long-term treatment with rhGH, beyond 
six months, even resulted in an increase of bone mass. Therefore, this suggests that 
besides an increase in activation frequency of bone remodeling units, long-term 
rhGH treatment may result in a loss of synchronization between resorption and 
formation with an apparent shift towards bone formation. 
Several studies in postmenopausal women have shown that a reduction of bone 
turnover, as can be induced by pamidronate, is accompanied by a transient increase 
of bone mass (for review see Heaney (32)). However, in the present study treatment 
with pamidronate only attenuated the GH-induced increase in bone turnover, but did 
not result in a reduction below pretreatment level. Therefore, it is unlikely that the 
observed gain in BMC during additional pamidronate treatment can simply be 
explained by the so-called "transient". A shift of the bone balance towards formation 
is more likely. As stated above this shift towards formation may be related to GH 
treatment. It is known that IGF-I can stimulate osteoblast-like cells (36). Furthermore 
the effects of GH treatment can be indirect via an increase in muscle mass and 
physical activity. However, an anabolic effect on bone of the raised PTH levels 
during pamidronate treatment can not be excluded. Although the mechanism for the 
anabolic action of PTH is poorly understood, GH is required for its effect in animals 
(37). As the volume to surface ratio of trabecular bone is higher than that of cortical 
bone, changes in bone turnover are more reflected in trabecular bone. This also 
explains the more pronounced change of BMC at the distal radius and lumbar spine, 
compared to the proximal forearm. 
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This study shows that the effects of GH-replacement therapy and bisphosphonates 
on renal phosphate handling are partly antagonistic and that these effects are 
probably not mediated through PTH. GH therapy results in an increased bone 
turnover and consequently in bone loss. Inhibition of bone turnover with the 
bisphosphonate pamidronate, prevents this initial loss and even results in an 
increase of bone mass. Additional studies are needed to see whether pamidronate 
interacts with long-term effects of GH on bone mass in GHD patients. 
Acknowledgements 
We want to thank the staff of the Clinical Research Unit for the excellent care of the 
patients. 
114 
Clinical aspects of GH therapy in adults 
REFERENCES 
1. Harbison MD, Gertner JM. 1990 Permissive action of growth hormone on the renal 
response to dietary phosphorus deprivation, J elin Endocrinol Melab. 70:1035·1040. 
2. Bouillon R. 1991 Growth hormone and bone. Harm Res. 36(Suppl 1):49·55. 
3. Lieberman SA, Holloway L, Marcus R, Hoffman AR. 1994 Interactions of growth hormone 
and parathyroid hormone In renal phosphate, calcium, and calciffjoj metabolism and bone 
remodeling in postmenopausal women. J Bone Miner Res, 9:1723-1728. 
4. Adami 5, Frijlink WB, Bijvoet OlM, O'Riordan JLH. Clemens TL, Papapoulos SE. 1982 
Regulation of calcium absorption by 1,25,dihydroxy-vitamln D-studles of the effects of a 
bisphosphonate treatment. Cafc Tissue Int. 34:317-320. 
5. Bonjour JP, Trechsel U, Taylor eM, Fleisch H. 1988 Parathyroid hormone-independent 
regulalion of 1,25(OH}2D in response to inhibition of bone resorption. Am J Physio!. 
254:E260·E264. 
6. Netelenbos JC, van Ginkel FC, Lips P, et al. 1991 Effect of a single infusion of 
aminohydroxypropylidene on calcium and bone metabolism in healthy volunteers monitored 
during 2 months. J Clin Endocrinol Metab. 72:223·228. 
7. Kaufman J-M, Taelman P, Vermeulen A, Vandeweghe M. 1992 Bone mineral status in 
growth hormone·deficient males with isolated and multiple pituitary deficiencies of childhood 
onsel. J Clin Endocrinol Melab. 74:118·123. 
8. Hyer SL, Rodin DA, Tobias JH, Leiper A. Nussey SS. 1992 Growth hormone deficiency 
during puberty reduces adult bone mineral density. Arch Dis Child. 67:1472·1474. 
9. Elgindy N, Grunditz R, Thoren M, Degerblad M, Sj6berg HE, Ringertz H. 1991 Long term 
follow-up of metacarpal cortical thickness and bone mineral density in panhypopituitarism. 
Radial Diagn. 32:326·330. 
10. Holmes SJ, Economou G, Whitehouse RW, Adams JE. Shalet SM. 1994 Reduced bone 
mineral density in patients with adult onset growth hormone deficiency. J Clin Endocrinol 
Metab.78:669·674. 
11. WUster C, Slencka E, Ziegler R. 1991 Erhahte pravalenz von osleoporose und 
arterjosklerose bel konvenlionell substituierter hypophysenvorderlappeninsuffizienz: bedarf 
einer zusmzllchen wachstumshormonsubstitution? Klin Wochenschr. 69:769-773. 
12. Black OM. Cummings SR, Genant HK, Nevitt MC, Palermo L, BrownerW.1992 Axial and 
appendicular bone density predicts fractures in older women. J Bone Miner Res. 7:633-638. 
13. Cummings SR, Black OM, Nevitt MC, et al. 1993 Bone density at various sites for 
prediction of hip fractures. Lancet. 341:72-75. 
14. Johansson AG, Burman P, Westermark K, Ljunghall S. 1992 The bone mineral density in 
acquired growth hormone deficiency correlates with circulating levels of insulin-like growth 
factor I. J Intern Med. 232:447·452. 
15. Bing-You RG, Denis M-C. Rosen CJ. 1993 Low bone mineral density in adults with 
previous hypothalamic-pituitary tumors: Correlations with serum growth hormone responses 
to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3. Calc Tissue 
Inl. 52:183·187. 
115 
Combined treatment of GH and pamidronale in GHD 
16. Salomon F, Cuneo RC, Hesp R, Sonksen PH. 1989 The effects of treatment with 
recombinant human growth hormone on body composition and metabolism in adults with 
growth hormone deficiency. N Engl J Med. 321:1797-1803. 
17. Jorgensen JOl, Pedersen SA, Thuesen l, Jorgensen J, Skakkebmk NE. Christiansen 
JS. 1989 Beneficial effects of growth hormone treatment in GH-deficient adults. Lancet. 
1 :1221-1225. 
18. Bengtsson B-A, Eden S, Bosaeus I, et al. 1993 Treatment of adults with growth hormone 
deficiency with recombinant human growth hormone. J Clin Endocrinol Metab. 76:309-317. 
19. Brixen K, Nielsen HK, Mosekilde l, Flyvbjerg A. 1990 A short course of recombinant 
human growth hormone treatment stimulates osteoblasts and activates bone remodeling in 
normal human volunteers. J Bone Miner Res. 5:609-618. 
20. Johansen JS, Pedersen SA, Jorgensen JOl, et al. 1990 Effects of growth hormone (GH) 
on plasma bone gla protein in GH-deficient adulls. J elin Endocrinol Metab. 70:916-919. 
21. Nielsen HK, Jorgensen JOl, Brixen K, Christiansen JS. 1991 Serum osteocalcin and 
bone isoenzyme alkaline phosphatase in growth hormone-deficient patients: dose-response 
studies with biosynthetic human GH. Calc Tissue Int. 48:82-87. 
22. Schlemmer A. Johansen JS, Pedersen SA, Jorgensen JOl, Hassager C, Christiansen 
C. 1991 The effect of growth hormone (GH) therapy on urinary pyridinoline cross-links in GH-
deficient adults. Clin Endocrinol (Oxn. 35:471-476. 
23. Whitehead HM, Bareham C, Mcilrath EM, et at 1992 Growth hormone treatment of adults 
with growth hormone deficiency: results of a 13-month placebo controlled cross-over study. 
Clin Endocrtnol (Oxn. 36:45-52. 
24. Binnerts A, Swart GR, Wilson JH, et al. 1992 The effect of growth hormone administration 
in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as 
well as on body composition. elin Endocrinol (Oxt). 37:79-87. 
25. Degerblad M, Eigindy N, Hall K, Sjtiberg H-E, Thoren M. 1992 Potent effect of 
recombinant growth hormone on bone mineral density and body composition in adults with 
hypopituitarism. Acta Endocrtnol (Copenh). 126:387-393. 
26. Vandeweghe M, Taelman P, Kaufman J-M. 1993 Short and long-term effects of growth 
hormone treatment on bone turnover and bone mineral content in adult growth hormone-
deficient males. Clin Endocrinol (Oxn. 39:409-415. 
27. O'Halioran OJ, Tsatsoulis A, Whilehouse RW, Holmes SJ, Adams JE, Shalet SM. 1993 
Increased bone density after recombinant human growth hormone (GH) therapy in adulls with 
isolated GH deficiency. J elin Endocrinol Melab. 76:1344-1348. 
28. Rosen T, Johansson G, Hallgren P, Caidahl K, Bosaeus I, Bengtsson B-A. 1994 
Beneficial effects of 12 months replacement therapy with recombinant human growth 
hormone to growth hormone deficient adults. Endocrinol Metab. 1 :55-66. 
29. van Berkum FNR, Birkenhiiger JC, van Veen lCP, et al. 1989 Non-invasive axial and 
peripheral assessment of bone mineral content: A comparison between osteoporotic women 
and normal subjects. J Bone Miner Res. 4:679-685. 
30. Erdtsieck RJ, Pols HAP, Aigra 0, Kooy PPM, Birkenhager JC. 1994 Bone mineral density 
in healthy Dutch women; spine and hip measurements using dual-energy x-ray 
absorpliomelry. Neth J Med. 45:198-205. 
116 
Clinical aspects of GH therapy in adults 
31. Nilas L, Borg J, Gotfredsen A, Christiansen C. 1985 Comparison of single- and dual-
photon absorptiometry in postmenopausal bone mineral/ass. J Nucl Med. 26:1257-1262. 
32. Heaney RP. 1994 The bone-remodelling transient: implications for the interpretation of 
clinical studies of bone mass change. J Bone Miner Res. 9:1515-1523. 
33. Caverzasio J, Bonjour JP. 1988 Influence of recombinant IGF-I (somatomedin-C) on 
sodium-dependent phosphate transport in cultured renal epithelium. Prog Clin Bioi Res. 
252:385-386. 
34. Caverzasio J, Montessuit C, Bonjour JP. 1990 Stimulatory effect of insulin-like growth 
factor-ion renal Pi transport and plasma 1,25·dihydroxyvitamin 03' Endocrinology. 127:453-
459. 
35, Holick MF, Adams JS. 1990 Vitamin D metabolism and' biological function. In: AVioli LV, 
Krane SM eds, Metabolic bone disease and clinically related disorders, Philadelphia: W.B. 
Saunders; 155-195. 
36. Kassem M, Blum WF, Ristelli J, Mosekilde L, Eriksen EF. 1993 Growth hormone 
stimulates proliferation and differentiation of normal human osteoblast-like cells in vitro, Calc 
Tissue Int. 52:222-226. 
37. Hock JM, Fonseca J. 1990 Anabolic effect of human synthetic parathyroid-hormone-(1-34) 
depends on growth hormone. Endocrinology. 127:1804-1810. 
117 
Combined treatment of GH and pamidronate in GHD 
118 
Clinical aspects of GH therapy in adults 
5 Treatment of Postmenopausal Osteoporosis with a Combination of 
Growth Hormone and Pamidronate. A Placebo-Controlled Trial 
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ABSTRACT 
It is known that growth hormone (GH) can induce accelerated bone turnover in GH 
deficient people as well as healthy elderly people. In this study we examined the effect 
of recombinant human GH (rhGH) on bone mineral mass and bone turnover in the 
presence of the bone resorption inhibiting agent, pamidronate. Also effects on body 
composition were stUdied. 
21 postmenopausal osteoporotic women were treated with the bisphosphonate 
pamidronate during twelve months. During the initial 6 months rhGH was administered 
(0.0675 IU/kg, 3 times/week) in a placebo-controlled fashion (10 vs. 11 patients). 
Bone mineral content (BMC) of the lumbar spine and femoral neck was measured with 
dual energy X-ray absorptiometry and BMC of the distal and proximal forearm with 
single photon absorptiometry. Body composition was measured with bioelectrical 
impedance and total body dual energy X-ray absorptiometry. Furthermore serum IGF-I 
and biochemical indices of bone turnover were measured. 
The group treated with rhGH showed a two- to three-fold increase in serum IGF-Ilevels. 
No effects on bone mineral mass were observed in the group treated with rhGH, while in 
women treated with pamidronate only a consistent increase of about 5 % was found at 
the lumbar spine. In both groups no change in BMC at the femoral neck and forearm 
was observed. 
Compared to baseline the biochemical measurements of bone turnover showed a 
decrease of about 50 % in the pamidronate-treated group, whereas in the group 
additionally treated with rhGH this effect was blunted. 
The body composition measurements showed clear effects of rhGH administration, i.e. a 
decrease of fat mass of about 5 % and an increase of lean body mass of about 3 %. 
However, these effects disappeared after the treatment with rhGH was stopped; fat 
mass as well as lean body mass returned to initial values. 
The present study suggests that treatment with rhGH blunted both the pamidronate-
induced accumulation of bone mineral mass and the reduction of biochemical markers 
of bone turnover. Furthermore the positive effect of rhGH on body composition 
disappears completely after cessation of treatment with rhGH. 
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INTRODUCTION 
Several approaches for the medical treatment of postmenopausal osteoporosis are 
available at present. Among these are estrogens, bisphosphonates, anabatic steroids, 
calcitonin, fluoride and vitamin D preparations (1-7). Most of these treatment schemes 
are effective by diminishing bone resorption, whereas only fluoride is able to increase 
osteoblastic activity (8,9). Recently Heaney argued that much of the apparent gain in 
bone mass produced by several agents currently employed to treat osteoporosis can be 
explained by the so called "bone-remodelling transient" (10). In other words the gain of 
bone induced by an inhibitor of bone resorption will only be transient because the 
associated rate of change in bone mass persists for only one remodelling period. A 
more fundamental change in bone mineral mass can only be obtained if a given drug 
can induce a change in the balance between formation and resorption at each individual 
remodelling locus. 
Recent evidence suggests a role for growth hormone (GH) as an osteotrophic factor. It 
is known that GH is responsible for longitudinal bone growth through a direct stimulation 
of chondrocytes and osteoblasts (11,12). In adults GH also activates bone remodelling 
(13,14). Furthermore, several studies indicate that in GH deficient (GHD) adults 
treatment with recombinant human GH (rhGH) results in an increase of bone turnover 
parameters and after long-term treatment even a rise of bone mineral mass has been 
observed (15-18). In addition studies of patients with endogenous high levels of GH 
(acromegaly) have shown a stimulated bone turnover and an increased bone mineral 
mass (19,20). 
Normal ageing and GHD show some striking common features. Both GHD as well as 
normal ageing are associated with decreases in protein synthesis, decreases in 
percentages of lean body and bone mass as well as with increases in percentage body 
fat (21-26). It is possible that reduced GH and IGF-I secretion may account, at least in 
part, for one or more of the above effects of ageing (27,28) and that elderly individuals 
might benefit from treatment with rhGH. In several studies administration of rhGH for 
periods varying from a few weeks to twelve months, resulted in improvement of nitrogen 
balance, an increase in lean body mass, and a decrease in percentage body fat 
(14,29-31 ). 
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Very litlle is known about the effects of rhGH in the treatment of postmenopausat 
osteoporosis. In a small study in which GH was administered in sequence with calcitonin 
in women with postmenopausal osteoporosis a small favourable effect was observed 
(32). In the present placebo-controlled study we tested whether rhGH might have an 
additional anabolic effect on bone formation in postmenopausal osteoporotic women 
treated with the bone resorption inhibitor pamidronate. Furthermore, the effects of rhGH 
on body composition were evaluated. 
MATERtALS AND METHODS 
Patients and treatment 
After review and approval of the protocol by the Ethical Committee of our institution, 
written informed consent was obtained from the patients. All 23 patients were Caucasian 
postmenopausal osteoporotic women with at least one non-traumatic vertebral fracture. 
Patients with any disorder known to affect bone mass were excluded from this study, as 
were women with a history of malignancy. All patients were treated with pamidronate. 
The patients were randomly assigned to receive either rhGH or placebo. 
All patients received during 12 months pamidronate as an enteric-coated tablet, 150 mg 
per day, orally on an empty stomach. During the initial six months rhGH or placebo was 
self administered by means of SUbcutaneous injection of 0.0625 IUlkg with a maximum 
of 4 IU, 3 times per week (monday, wednesday, friday). In a pilot-study this dose 
resulted in high normaIIGF-llevels. Treatment was double blinded with regard to rhGH 
or placebo. rhGH (Humatrope) and placebo was supplied by Eli Lilly Co. Indianapolis, 
tN., USA. Placebo vials were indistinguishable from rhGH vials. 
In patients with a calcium intake below 1000 mg (according to dietary history), a Ca-
Sandoz effervescent tablet containing 0.5 g elemental calcium was given. This applied 
to 5 patients in the GH-group and 6 patients in the placebo group. Compliance was 
measured by means of tablet and vial counting. The baseline characteristics of the 
patients are shown in Table 1. 
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TABLE 1. Clinical and biochemichal characteristics of the ~alients 
Characteristic rhGH (n=10) placebo (n=11) 
mean range mean range P 
Age (yr) 63.5 57-74 62.8 55-72 NS 
YSM (yr) 20.2 7-30 14.4 5-27 NS 
BMI (kg/m') 25.0 19.6-27.4 25.6 19.0-32.5 NS 
Height (cm) 162.5 149-179 160.5 153-178 NS 
Weight (kg) 65.3 56.0-77.5 66.7 45.0-89.1 NS 
BMCsPINE (gHa) 32.7 23.4-39.7 31.8 21.2-44.6 NS 
BMCFEM NECK (gHa) 3.5 3.1-4.4 3.6 1.9-6.0 NS 
BMCWARD (gHa) 1.6 1.2-2.4 1.7 1.0-3.5 NS 
BMCTROCH (gHa) 8.2 4.6-14.3 7.3 3.2-11.6 NS 
BMC SPADIsT (U/cm) 29.4 22.2-38.2 27.8 14.0-40.3 0.05 
BMC SPApRox (U/cm) 30.8 19.5-38.4 30.3 16.3-42.9 NS 
Serum calcium (mmol/L) 2.28 2.10-2.40 2.29 2.15-2.44 NS 
Serum phosphate (mmol/l) 1.13 0.99-1.27 1.19 0.81-1.41 NS 
Creatinine (r,molll) 67 48-91 78 49-113 NS 
APase (U/I) 57.2 44-82 79.5 37-124 <0.05 
IGF-I (nmol/l) 20.0 9.6-33.0 24.2 13.2-48.0 NS 
Osteocalcin (/1gll) 3.0 1.0- 6.5 4.7 0.6- 8.5 NS 
Procollagen I (r'gll) 104.2 44-286 108.1 74-178 NS 
2 hr fasting: 
Urinary OH-proline 20.8 9.6-39.4 23.5 10.2-60.0 NS 
(mmol/mol creat) 
Urinary pyrilinks 80.3 36.7-171.0 51.3 14.6-88.1 NS 
(nmol/mol creat) 
NS: no significance between groups. 
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Bone mineral mass measurements 
Single photon absorptiometry (SPA) of the right forearm was performed at the distal and 
proximal sites with an interval of 3 months using a Nuclear Data 1100a scanner (33). 
The (fat-corrected) results are expressed as bone mineral content (BMC; arbitrary units, 
U/crn). The coefficient of variation in our hands is 1.9 % for the distal site and 1.0 % for 
the proximal site. 
Dual energy X-ray absorptiometry (DXA; Lunar DPX-L, Lunar Radiation, Madison, WI, 
USA) was performed at the lumbar vertebrae 2-4 (L2-4) and in the left proximal femur: 
the femoral neck, Ward's triangle and trochanteric region according to the instructions of 
the manufacturer (34). BMC is expressed as grams of bone mineral (g/crn). For 
osteoporotic women the coefficient of variation is 1.5% for the lumbar spine and 1.8, 2.4 
and 2.8% in the femoral neck, Ward's triangle and trochanteric region, respectively. 
Quality assurance, including calibration with the standard of the machines (SPA and 
DXA), was performed routinely every working day. No drift was observed during the 
whole study period. 
Body composition 
Body composition was measured after an overnight fast by the bioelectrical impedance 
method (BIA) with a body composition analyser (RJL-systems BIA-101 Detroit, MI, USA) 
as described previously (35,36). Through regression equation, fat free mass (FFM) was 
calculated. Fat mass was calculated by subtracting FFM from body weight (36). 
Body composition was also measured by using the DPX-L densitometer. The instrument 
measures fat mass, lean mass and bone mineral content. The method is well validated 
(37). 
Biochemistry 
At baseline and after 1, 3, 6, 9, and 12 months the following fasting serum parameters 
were determined: Calcium, phosphate, alkaline phosphatase, creatinine, albumin, 
glucose and glycosylated haemoglobin (HbA,C) with standard methods. 
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Insulin-like growth factor-I (IGF-I), osteocalcin and procollagen type 1 (PICP) with 
radioimmuno-assay (RIA) (Medgenix Diagnostics, Brussels, Belgium; Incstar 
Corporation, Stillwater, USA and Orion Diagnostica, Espoo, Finland respectively). 
At baseline and after 3, 6, 9 and 12 months the following urinary parameters were 
determined: Fasting (2h) hydroxyproline by Hypronosticon (Organon Technika, Oss, 
The Netherlands) and excretion of free deoxypyridinoline by enzyme linked immuno 
sorbent assay (Pyrilinks D, Metra biosystems, Palo Alto, USA). 
All samples were collected after an overnight fast on the day after administration of 
rhGH or placebo. 
Statistics 
Values are expressed as means ± SEM. At baseline differences between groups were 
tested by Student's t-test for unpaired data, with a P value of < 0.05 for significance. 
Statistics within and between treatment groups were performed by means of repeated 
measures analysiS of variance (rmANOVA). The dependent variable is assumed to have 
a linear trend relationship with time; in the model the slope is different between the two 
treatment groups. In the GH group the model includes additional effects after stopping 
rhGH in month 9 and 12. 
If the rmANOVA resulted in a significant main effect between treatment groups, we 
performed a Student's t-test posthoc analysis for paired data within groups and for 
unpaired data between groups, with a P value of < 0.05 for significance. 
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RESULTS 
Side effects, baseline values 
Initially 23 patients entered the study. 12 patients were treated with pamidronate only 
(placebo-group). One of these patients decided to stop at 4 months, because of gastric 
complaints, related to the use of the bisphosphonate. The 11 patients of the other group 
were treated with APD and rhGH (rhGH-group). In this group one patient was taken out 
at 3 months because of cardiac complaints related to fluid retention (minor cardiac 
failure, which was treated with diuretics). The remaining 21 patients (placebo-group; 
n=11, rhGH-group; n=10) completed the 12 months study period and were eligible for 
evaluation. Except for 1 patient complaining temporarily of gastric complaints no side 
effects were observed in these patients. rhGH injections were tolerated well, no dose 
adjustments were necessary. 
The baseline values are presented in Table 1. No significant differences as to age, or 
years since menopause (YSM) were found between both groups. Also anthropometric 
data were comparable. The initial bone mass measurements showed no significant 
differences except for the distal forearm BMC, measured with SPA (Table 1). Body 
composition did not show any differences at baseline when calculated with BIA or 
measured with DXA. The baseline biochemical measurements showed a higher serum 
alkaline phosphatase (P <0.05) in the placebo-treated group, otherwise there were no 
differences (Table 1). 
Longitudinal bone mass measurements 
The time course of the different bone mineral mass measurements are shown in Fig. 
1A-D. For the lumbar spine a rapid increase in the placebo-group was observed after 
three months with a much slower increase during the subsequent nine months. For the 
rhGH-group no significant changes were observed during (0-6 months) and after 
cessation (6-12 months) of treatment. In the femoral neck (as well as the Ward's triangle 
and trochanteric region) no significant changes during the whole treatment period (12 
months) for either group were observed. For the distal forearm a similar pattern as in the 
lumbar spine was found, however, no significance was reached between both groups. 
The proximal forearm showed no clear changes in either group. 
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Fig. 1 Course of the BMC. Treatment with Pamidronate during twelve months. Treatment with rhGH or 
placebo during the first six months. Measurement at 0, 3, 6, 9 and 12 months. Results are 
presented as mean ± SEM and as percentage of inUial value. For statistical analyses see matenal 
and methods section. ~ 0 -; pamidronate. -. -; GH + pamidronate 
Significance within groups VS, baseline: # P < 0.05, # # P < 0.01. 
Significance beween groups :* P < 0.05, ** P < 0.01. 
Body composition 
Baseline measurements for body composition showed a correlation between fat mass 
assessment by BIA and DXA (r = 0,74, P <D,DDt), Also the changes in time measured 
by the two methods were well correlated (r = 0,85, P <D,DDt), 
In the placebo-group no changes in body composition were observed during the year of 
treatment. In the rhGH-group, irrespective of the method used, a significant decline of 
the percentage fat of about 5-7 % compared to initial values occurred, After the 
treatment with rhGH was withdrawn an increment of fat mass occurred, reaching pre-
treatment levels within 3 months, when measured by BIA (Fig, 2A), 
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Total body DXA measurements were 
not performed at 9 months (Fig. 28). 
When lean body mass was analysed 
by DXA, again no changes in the 
placebo-group were found whereas 
a significant increase in lean mass of 
about 2.5 % after 3 months was 
found in the rhGH-group (Fig. 2C). 
Again, these changes disappeared 
after treatment with rhGH was 
stopped at six months and returned 
to pre-treatment values. 
Biochemical parameters 
Serum levels of IGF-I increased 
rapidly after 1 month in the rhGH-
group and stabilised during rhGH-
treatment. After cessation of rhGH-
treatment a rapid return to pre-
treatment values was observed (Fig. 
3). ~~fLrl~~-r~~-r~~-r~~-r Serum Ca, P and creatinine did not 
12 o 3 6 9 
months change during the treatment period 
between or within groups. During the 
Fig. 2 Course of the fat mass: measured by impedance 
(BIA) (a) and OXA (b). Course of lean body mass 
treatment period no changes in 
glucose metabolism (glucose, 
glycosylated Hb) were observed in by DXA (c). See also the legend to Fig. 1. 
both groups. 
The relative changes of serum alkaline phosphatase, osteocalcin, procoliagen type 1 
over time within and between both treatment groups are depicted in Fig. 4 A-C. 
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In the placebo-group as well as in 
the rhGH-group a significant 
increase in alkaline phosphatase 
was found after 1 month. From 6 
months onwards in the placebo-
group and from 9 months onwards in 
the GH-group a significant decline of 
serum alkaline phosphatase was 
found. For osteocalcin a rapid 
decrease in the placebo-group was 
observed, whereas in the rhGH-
Flg.3 Course of the serum IGF-Ilevels. Treatment with group a non-significant increase 
Pamidronate during twelve months. Placebo- was observed. From 3 months 
controlled treatment with GH during first six 
months. Measurements at 0, 1, 3, 6, 9 and 12 
months. Results are expressed as mean ± SEM 
in nmolVL. See also the legend to Fig. 1. 
onwards a significant difference 
between both treatment groups 
existed. 
Proccllagen type 1 showed a small increase after 1 month in the rhGH-group, followed 
by a non-significant decline (ccmpared to initial values). In the placebo-group an instant 
decline was observed from initiation of treatment onwards. 
In the placebo-group, urinary OH-proline (ccrrected for urinary creatinine) showed a 
rapid although not significant decline, whereas in the rhGH-group no changes at all 
were observed (Fig 4D). Also urinary free deoxypyridinoline, which is a more specific 
marker of bone resorption, showed only in the placebo-group a temporarily significant 
decline. 
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DISCUSSION 
In this study, in which we treated postmenopausal osteoporotic women for one year with 
pamidronate, half of the women received during the initial six months also rhGH in a 
placebo-controlled manner. No additional effect of rhGH treatment was found on bone 
mineral mass. On the contrary, the beneficial effect of pamidronate on bone mass was 
blunted by the addition of rhGH. 
In the placebo-group, treated with pamidronate only an increase of bone mineral mass 
at sites representing cancellous bone (lumbar spine and distal forearm) was observed, 
whereas no Significant changes were observed at sites merely containing cortical bone 
(femoral neck and proximal forearm). A similar gain of bone mineral mass, explained by 
the so-called "transient" (10), has been reported by other investigators using 
bisphosphonates (4,38). 
In the rhGH-group a rapid and consistent increase of circulating IGF-I levels was 
observed, indicating that the dose of rhGH used (0.0625 IUlkg, 3 times/wk) was 
sufficient to reach a level which is supraphysiological for this age group. After withdrawal 
of rhGH administration, IGF-I values returned to baseline values. Other investigators 
recently showed that in postmenopausal women a comparable dosage of rhGH as used 
in our study induces a prompt and sustained increase in bone remodelling (14). 
However, in our osteoporotic women the simultaneous addition of pamidronate appears 
to attenuate this rhGH-induced increase in bone turnover. Therefore, the absence of a 
clear change in the activation of bone remodelling units, as reflected by the markers of 
bone turnover, might explain that in the rhGH-group no change of bone mineral mass 
was observed. It became only apparent after the study that the baseline bone turnover 
rate appeared somewhat lower in the rhGH treated palients. However, this does not 
detract from our main conclusion that combined treatment of rhGH and pamidronate 
does not result in a positive effect on bone mineral mass. 
The present combination of therapeutic modalities in the treatment of postmenopausal 
osteoporosis was based on the assumption that it might be possible to activate bone 
formation by rhGH in the presence of an anti-resorptive therapy (pamidronate). 
However, this turned out not to occur. Several possible explanations can be given. First, 
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we have to take into account that the postmenopausal women we have treated are not 
growth hormone deficient and may thereby be less sensitive to supraphysiological 
dosages of growth hormone. However, several studies have indicated that both short-
(30) and long-term (14) treatment with comparable dosages rhGH resulted in an 
increased bone turnover. In the present study we also observed in the rhGH treated 
patients at least initially a trend towards an increase of all bone formation markers, 
which was not accompanied by an increase of bone resorption. However, this apparent 
shift of the balance towards formation did not result in a clear rise of bone mass. 
Secondly, the treatment period might have been too short to observe an osteotropic 
effect of rhGH. In GHD patients only long-term treatment wilh rhGH beyond six months 
resulted in a sustained increase of bone mineral mass (18). 
Thirdly, the present scheme of continuous rhGH and pamidronate treatment might have 
inhibited potential beneficial effects of rhGH on osteoblastic function. Whether it may be 
necessary to administer rhGH cyclically in tandem with pamidronate remains to be seen. 
Previous results (32) using GH in sequence with the bone resorption inhibitor calcitonin 
do not support the idea that such an approach indeed results in a more favourable 
response than could be expected from treatment wilh an inhibitor of bone resorption 
alone. 
Finally, one can argue that the number of patients in this study is too small. However, 
based on the present results iI is highly unlikely that inclusion of more patients will 
change the results towards a more favourable effect of combined treatment versus 
treatment wilh pamidronate alone. 
rhGH treatment affects body composition with a decrease of fat mass and increase of 
lean body mass (24,29,39). Body composilion in this group of elderly patients also 
changed accordingly during rhGH treatment with a decrease of fat mass and a rise of 
lean body mass. The changes observed were comparable to those obtained in GHD 
adult individuals during rhGH replacement therapy (29,40). 
Still, the methodology used in this study to measure body composition merits some 
further comments. The validalion of the BIA method has not been carried out for 
different patient groups. The hydration status significantly influences the outcome, in the 
sense that a slight dehydration, as might be the case in the elderly, overestimates the 
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percentage body fat (41,42). The DXA method is better validated and measures fat 
directly (43). The DXA technique does not distinguish between intra- and extracellular 
water. The increase in free fat mass as observed in our patients during GH treatment 
indicates an accumulation of body water. The decrease in fat mass, as measured by 
DXA, however, is a true phenomenon. As the changes in body composition, measured 
by BIA and DXA are closely in parallel, we consider these changes as clinically 
significant. 
Taken together our results clearly show that simultaneously started combined treatment 
with rhGH and pamidronate during six months offers no new approach in the treatment 
of postmenopausal osteoporosis. Even if long-term treatment with rhGH results in a 
favourable shift of the balance between bone resorption and formation than it is still 
questionable whether such an effect justifies long-term treatment given the side-effects 
of GH-treatment and its high costs. Nevertheless, further studies are needed to 
elucidate whether in selected cases with a low bone turnover administration of rhGH in 
sequence with an inhibitor of bone resorption is a useful option. 
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6 The Effects of Long-Tenn Growth Honnone (GH) Replacement 
Therapy in Patients with Adult Onset GH-deficiency. 
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ABSTRACT 
GH-deficiency in adults (GHDA) has beccme reccgnized as a specific clinical syndrome. 
Its main features are changes in body ccmposilion, decreased psychological well-being, 
reduced bone mineral ccntent and disorders in lipids metabolism. We report here the 
results of the effects of long-term rhGH replacement therapy in twenty patients with adult 
onset growth hormone deficiency. There was an initial placebo-ccntrolled phase of six 
months, followed by a period of open treatment for both patient groups of 12 months. 
We measured body composition with several techniques in order to ccmpare these 
techniques. Body composition was measured by bioelectrical impedance analysis (BIA), 
anthropometry, skinfolds (SF) and total body dual energy x-ray absorptiometry (DXA). 
Also measurements were performed of bone turnover parameters and bone mass, 
quality of life, carbohydrate and lipid metabolism. There was a significant difference in 
the age between the groups (P =0.034). Eighteen patients ccmpleted the eighteen 
month study period. Fifteen patients reached normal IGF-I levels. Three patients 
needed dose reduction. Gluccse metabolism was slightly affected temporarily. Body 
ccmposition changed significantly, with a decrease in fat mass (FM) and an increase of 
fat free mass (FFM). These changes were detected well by SF but not by BIA. Quality of 
life measurements showed modest improvement. Lipid profile improved significantly by 
an elevation of HDL-cholesterol levels. Bone turnover was activated, in favor of bone 
formation. However, this did not result in an increase in bone mineral ccntent 
measurements. 
We ccnclude that long-term GH replacement therapy in patients with adult onset GHD 
results in favorable effects on body ccmposition, quality of life, HDL-cholesterol levels, 
and bone turnover. Changes in body ccmposition are easily and accurately detected by 
skinfold anthropometry and not by bioelectrical impedance analysis. As skinfold 
anthropometry is an easy, patient-friendly and cheap procedure, this method should be 
used in the evaluation of the efficacy of GH replacement therapy in GHDA patients. 
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INTRODUCTION 
GH-deficiency in adults (GHDA) has beccme reccgnized as a specific clinical syndrome 
(1). Its main features are changes in body ccmposition (2-5), reduced bone mineral 
ccntent (6-8) and a decreased psychological well-being (9-12). Olher reported findings 
are alterations in renal function (13), reduced cardiac function and premature 
atherosclerosis with increased cardiovascular morbidity and mortality (14-17), disorders 
in lipid and carbohydrate metabolism (18), and impaired thermoregulation (19). 
An important aspect of GHD is an increase in body fat and a decrease in lean body 
mass ccmpared to age-, sex-, height- and weight- matched ccntrols (2,20-22). In 
childhood onset GHD GH treatment reduced the amount of subcutaneous (sc.) fat (23), 
whereas a reduction mainly in sc. and visceral adipose tissue was demonstrated during 
GH replacement in GHD adults (22,24). In another study in children with GHD an 
increase in muscle mass and a decrease in total body fat were reccrded (25). These 
changes were also observed in GHD adults by using several techniques of body 
ccmposition assessment (22,24,26-30). The validity of measuring changes of body 
ccmposition by bioelectrical impedance analysis (SIA) in GHD is debated and might be 
not suitable in evaluating effects of GH replacement therapy (3,31). In this study we 
investigated and ccmpared the long-term effects of GH on body ccmposition by SIA, 
total body dual energy x-ray absorptiometry (DXA) and skinfold anthropometry. 
We report here the results of the effects of rhGH replacement therapy in twenty patients 
with adult onset growth hormone deficiency. There was an initial placebo-ccntrolled 
phase of six months, followed by a period of open treatment for both patient groups of 
12 months. We measured body ccmposition with several techniques in order to 
ccmpare these techniques. Also measurements were performed of bone turnover 
parameters and bone mass, quality of life, carbohydrate and lipid metabolism, and 
physical performance. 
139 
Longwtenn effects of GH in Adult Onset GHD 
MATERIALS AND METHODS 
Patients 
GHD was considered to be present, when there was a history of pituitary disease, in 
combination with maximum GH levels in at least one provocation test below 5 mg/L. 
Twenty patients (13 males and 7 females, mean age 47 yr., range 30-59) were included 
in the study (Table 1). In the twenty patients that entered the study, thirteen patients had 
undergone transsphenoidal hypophysectomy: all but three of these patients, who had a 
craniopharyngeoma, received additional radiation therapy. Two patients had undergone 
transfrontal hypophysectomy and additional radiotherapy. Two patients received primary 
radiotherapy (one with Cushing's disease and one with prolactinoma). Two received 
primary medical treatment of prolactinoma. One patient presented with an enlarged 
pituitary fossa, liquorrhoea and partial hypopituitarism. Patients, who previously 
received GH replacement therapy, were excluded. All patients received conventional 
replacement therapy, of which the doses, apart from temporary increases (less than one 
week) in corticosteroids at the event of intercurrent illnesses, were not altered during the 
entire study period. The six patients with a prolactinoma received dopamine agonist 
therapy. 
Protocol 
The trial had a run-in period of four weeks, after which the patients were randomized 
into two groups to receive (double blind) treatment with recombinant human GH (rhGH) 
or placebo for six months. The GH dose was 6.25 ~glkg.day in the first month and 12.5 
~g/kg.day (0.236 IU/kg.week) for the following five months. Maximum dose was 1000 
~g/day (2.7 IU/day). After six months all patients continued on rhGH therapy, at which 
time the dose was again reduced to 6.25 ~g/kg.day for one month. From the seventh 
month onward all patients were treated with 12.5 ~g GHlkg.day. The aims and methods 
of the study were explained to the patients and written informed consent was obtained 
before the study, which was approved by the ethics committee of the University Hospital 
Dijkzigt (Rotterdam, The Netherlands). 
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TABLE 1. Clinical and biochemical characteristics of the patients included in 
the stud~. 
Characteristic rhGH Placebo 
Group (n=9) Group 
(n=9) 
Mean age (yr) 42 ±2.8 52±2 • 
Range 30-53 39-59 
Sex (M1F) (7/2) (4/5) 
Known duration of GHD (yr) 10 10 
Range 2-16 2-17 
Diagnosis 
Cushing's disease 2 1 
Prolactinoma 3 2 
Chromophobe adenoma 3 3 
Craniopharyngeoma 1 3 
Conventional replacement' 
T,A 1 
T,G 1 2 
A,G 1 1 
T,A,G 6 5 
T,A,G,DI 1 
IGF-I baseline (ng/mL) (± SEM) 132 ± 23 103 ± 16 
Normal range (91-356) 
Range 52-263 41-204 
Ht (cm) 177 172 
Range 162-188 161-186.6 
Wt (kg) 86 87 
Range 68.9-103.4 63-104.7 
Body Mass Index (kg/m') 27.5 29.5 
Range 22.6-36.8 24.3-35.2 
, T, thyroid deficiency; A, adrenal deficiency; G, gonadal deficiency; DI, diabetes 
insipidus . 
• P< 0.05 
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Methods 
Routine methods were used for the hematological and chemical measurements and 
measurement of cholesterol, HDL-cholesterol (HDL-c), LDL-cholesterol (LDL-c) and 
VLDL-cholesterol (VLDL-c). 
Glucose metabolism 
An oral glucose tolerance test (OGTT, 75g glucose) was performed at several visits 
during the study. Plasma blood glucose was measured at 0, 30, 60, 90 and 120 min. At 
the same points serum samples were collected for insulin determinations. Insulin was 
determined by RIA using a commercially available kit (INCSTAR Corp., Stillwater, MN; 
intraassay CV, 6.4-10.9%; interassay CV, 8.5-10.0%). Impaired glucose tolerance was 
defined as a 2-h value between 7.8 and 11.1 mmollL with another value during the 2-h 
test period equal to or greater than 11.1 mmollL (32). The total areas under the glucose 
(AUCG, mmol.hlL) and insulin (AUCI, mU.hIL) curve were calculated trapezoidally. Also 
calculations were made to measure peripheral insulin resistance according to methods 
described earlier (33). Glycosylated hemoglobin (HbA,C) was assessed using high-
performance liquid chromatography using routine methods (intraassay CV, 0.41 %-
1.99%; interassay CV, 1.1-1.62%). HbA,C values exceeding 6.3% of the total 
hemoglobin were regarded as abnormal. 
Insulin-like Growth Factor I (IGF-I) determinations were performed by a RIA kit 
(Mediagnost, TObingen, Germany) (34). Normal range in adults 20-30 yr.: 115-340 
nglmL; 50-60 yr.: 97-295 nglmL. IGF binding protein-3 (IGFBP-3) was determined by 
IRMA using a non-isotopic sandwich assay (35). Normal range for adults 1800-4800 ngl 
mL. 
Bone turnover parameters 
Osteocalcin was determined using a RIA kit (Diagnostic Systems Laboratories, 
Webster, TX; intraassay CV, 5.4-8.4%; interassay CV, 5.5-14.7%). Normal range 1.8-
6.6 nglmL. 
142 
Clinical aspects of GH therapy in adults 
Deoxypyridinoline cross-links (DPD, pyrilinks-D) were quantified by using a high-
performance liquid chromatography technique described earlier (36), (intraassay CV, 
3.4%; interassay CV, 8-12%). Concentrations of urinary DPD were expressed relative to 
urinary creatinine (nmol/mmol creatinine). 
Body composition 
Body composition was measured by bioelectrical impedance analysis (BIA), 
anthropometry, skinfolds (SF) and total body dual energy x-ray absorptiometry (DXA). 
Estimation of fat free mass and fat mass was performed using a Holtain Body 
Composition Analyzer (Holtain Ltd., Croswell, Dyfed, England) as described earlier 
(4,31 ). 
DXA analysis was performed with a Lunar DPX Densitometer (Lunar Corp., Madison, 
WI) (37). DXA directly measures fat mass, lean tissue mass and total body bone mineral 
content (38). 
Anthropometric assessment of body composition was performed by measuring the sum 
of skinfold thickness with calipers (Holtain Ltd., England) at biceps, triceps, subscapular 
and suprailiac sites at the left side of the body according to standardized guidelines. 
Through equations developed by Durnin and Womersley, body density, body fat and fat 
mass were calculated (39). 
Quality of life 
For assessment of quality of life part I of the Nottingham Health Profile (NHP) was used 
(40). This is a self-rating questionnaire by which perceived health problems and their 
impact on task performance in the physical, mental and social spheres are measured. 
Part I of the NHP consists of 38 statements covering six sections, each of which refers 
to a separate area of functioning. The sections comprise physical mobility, pain, sleep, 
energy, social isolation, and emotional reactions. Respondents are required to read 
each statement and to tick either 'yes' or 'no', depending on whether that problem 
applies to them in general at the time. 
143 
Long-tenn effects of GH in Adult Onset GHD 
The sections contain between 3 and 9 items, each of which has received a scoring 
weight in order to make the maximum score per section 100. Thus a respondent 
affirming all the statements in one section would obtain a score of 100. 
Several studies have established the validity and reliability of the NHP (41,42). Validity 
and reliability of the Dutch adaptation were found good, with exception of the section 
social isolation (43). 
Bone mass measurements 
Lumbar bone mass (lumbar vertebrae, L2-L4) was measured with the Lunar DPX Bone 
Densitometer (Lunar Corp., Madison, WI) (44). The coefficient of variation (CV) in 
normal subjects for DXA was 1.1 % (37). The results are expressed as BMC (g 
hydroxyapatite (Ha)). Quality assurance including calibration with the standard of the 
machine was performed routinely every morning. 
Single-Photon Absorptiometry (SPA) of the right forearm was performed at the distal 
and proximal sites using a Nuclear Data 1100a scanner (45). The (fat-corrected) results 
are expressed as BMC (arbitrary units (U) per em). The CV in our institution is 1.9% for 
the distal site and 1.0% for the proximal site (46). 
144 
Clinical aspects of GH therapy in adults 
RESULTS 
There was a significant difference in the age between the groups (P =0.034). Other 
baseline characteristics were not significantly different. Eighteen patients completed the 
eighteen month study period. One patient, who was in the 5th month of the placebo 
period, decided to stop due to marital problems. Another patient stopped after 7 months, 
in the open phase of the study, because of complaints of arthralgia and swelling mainly 
localized in the hands. There were no complaints in the placebo period. Reported 
complaints during active treatment were arthralgia in 12, muscle aches in 10, ankle 
edema in 6, occasional headache in 6, paresthesias in 4, palpitations in 3, and acne in 2 
patients. Slight hypertension developed in one patient. Almost all complaints resolved 
spontaneously. One patient needed short-term (two weeks) diuretics because of edema. 
In two patients dose reduction was performed, one because of persisting invalidating 
arthralgia, the other one because of ankle edema persisting after diuretic therapy. 
There were no significant changes in leukocyte count, hemoglobin concentration, serum 
treatinin, sodium, potassium, calcium and liver enzymes. Mean blood pressure, heart 
rate, and electrocardiograms did not change in both groups during the entire study 
period. No GH antibodies were found. 
IGF· I and IGFBP·3 
Mean IGF·I levels were lowered and not significantly different between groups at 
baseline. Only two patients in the GH group had IGF·llevels that were within the normal 
range when adjusted for sex and age compared to normals (one male 30 y, IGF·I 141 
ng/mL, and another male 42 y IGF·I 180 ng/mL). After the initiation of GH replacement 
therapy, there were significant differences versus baseline and between groups (Fig. 
1A). IGFBp·3 levels were also not significantly different between groups at baseline. 
Mean levels were in the normal range for adults. After the initiation of GH replacement 
therapy, there were significant differences versus baseline and between groups 
(Fig.1B). Fifteen patients reached normal IGF·I levels during GH replacement therapy, 
while in three patients IGF·I levels higher than 340 ng/mL were recorded at eighteen 
months. 
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Fig. 1 A-C. 
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Glucose metabolism 
Overnight glucose had elevated significantly after twelve weeks of GH treatment in the 
group that first received placebo treatment (4.2 ± 0.1 vs. 4.6 ± 0.1 mmollL, P < 0.001). 
During continued treatment overnight glucose decreased and eventually were not 
significantly different anymore from baseline. Apart from this, there were no significant 
between, nor within group differences in glucose or insulin levels measured overnight 
and during OGTT, nor in AUGG or AUGI or measurements of peripheral insulin 
resistance. HbA,G levels increased significantly during GH treatment within groups. No 
statistically significant difference between groups was reached (Fig. 1 G). In the group 
that started GH therapy at six months a significantly elevated HbA,G was found at six 
months of active treatment (Le. 12 months of the trial period) which was maintained 
during the remaining six months. At nine and twelve months (Le. 15 and 18 months of 
the trial period), however, HbA,G levels had again decreased significantly vs. the 
maximum at six (12) months. In the other treatment group the same pattern was 
observed. However, the decrease of HbA,G levels at 15 and 18 months did not reach 
significance (Fig. 1 G). 
Body composition 
Body composition measurements before the start of therapy demonstrated, by all 
techniques, differences between groups in fat mass and fat free mass. This was 
probably due to the significant difference in age between the groups. These differences 
in fat mass and fat free mass, however, were not statistically significant. Body 
composition changed significantly, with a decrease in fat mass (FM) and an increase of 
fat free mass (FFM), which were comparable but not identical among the three 
techniques that were used. When compared to placebo there was a significant 
difference in FM between groups at six months when assessed by SF (FMsF, P < 0.05), 
but not by DXA (FMDXA, P = 0.056). 
Within groups FMDXA had decreased after 6 months of GH therapy and after 12 months, 
respectively. FMDXA: 20.2 ± 2.8 kg (baseline) vs. 17.8 ± 3.6 kg (six months), P < 0.05 and 
vs. 19.1 ± 3.8 kg (18 months), P = n.s., in the group that started with GH. FMDXA: 25.9 ± 
2.6 kg (baseline) vs. 23.0 ± 2.8 kg (18 months), P = 0.015, in the group that started with 
147 
Long-tenn effects of GH in Adult Onset GHD 
35 
30 
25 
'0 
15 
10 
5 
0 
3' 
(J) 30 
E 
CO" 
"-
0)'0 
.Q 
:s2 1S 
10 
5 
o 
30 
25 
20 
15 
10 
5 
o 
fat mass fat free mass 
GH IPLACEBOI OH I PLACEBO I GH GH 
a 
# # # d # # # 6. 
60 
Iii 55 50 
Igfl I I • I I I t:lnt:llHlnn 
0 3 6 9 12 15 ,. 0 3 6 • 12 15 18 0 3 6 9 12 15 18 0 3 6 9 12 15 ,. 
GH I PLACEBOI GH 
# # # # # # 
b 
• 
66 e 
GH I I PLACEBOI GH 
#### ### 
I 
# 
• 
IIUIU 60 55 50 
Igfl I I • • •• f;l f;l f;l f;l f;l n n 
o 3 6 9 12 15 18 0 3 6 9 12 15 f8 o 3 6 9 12 15 18 0 3 6 9 f2 15 18 
GH 
c # 
o 6 
Fig. 2 A-F 
148 
I PLACEBo I GH 
,. o G ,. 
65 
60 
55 
50 
f 
o 
months 
GH I PLACEBO I 
# # # 
II II 
6 ,. o 6 
Fat mass (FM) measurements (a-c) and fat free mass (FFM) measurements (d-f) by BIA 
(a,d), SF (b,e) and DXA (e,f) .• P < 0.05 within group vs. six months. See also legend to 
Fig. 1. 
GH I 
# 
• 
,. 
Clinical aspects of GH therapy in adults 
50 15 
~ 
40 ." 10 
~ .:.: 
." 
~ 
.:.: ... 5 
~ 30 
'" g :;; 0 • , A' U. 
20 ~ :;; .. ·5 
" U. :!: 
10 ., 
·10 .., 
,·0.46 r = 0,89 
0 ·15 
0 10 20 30 40 50 ·15 ·10 ·5 0 5 10 15 
FMBIA (kg) delta FMBIA (kg) 
50 15 
~ 
40 ." 10 
.:.: ~ ~ 
." 
.:.: 30 " 
5 
~ >< 
" 
0 
>< :;; 0 Q 20 U. :;; 
·5 U. .. 
10 0 :!: ., 
·10 
, • 0.89 .., ,·0.43 
0 
·15 
0 10 20 30 40 50 
·15 -10 ·5 0 5 10 15 
FMBIA (kg) delta FMBIA (kg) 
50 10 
~ 
." 
40 .:.: 
~ ~ 5 
." 
" .:.: 30 >< ~ 0 
" 
:;; 0 
>< Q 20 U. :;; 
.. u. ... ·5 
10 ., 
.., 
0 ·10 
0 10 20 30 40 50 ·10 ·5 0 5 10 
FMsF (kg) delta FMsF (kg) 
Fig. 3 Correlations between absolute values and delta changes of fat mass as measured by BIA, SF and 
DXA 
149 
Long·tenn effects of GH in Adult Onset GHD 
placebo. In this group, there was a slight reduction in fat mass in the placebo period, 
which did not reach significance, however (Fig. 2A-C). 
Increases in FFMBIA were not significant in the GH group. FFMsF and lean mass by DXA 
(LMDXA) had significantly increased. (LMDXA: 63.1 ± 3.4 kg (baseline) vs. 66.0 ± 3.9 kg 
(18 months), P = 0.008). In the group that started GH replacement at six months there 
was a significant increase in FFM by SF and DXA in the placebo period. (LMDXA: 58.1 ± 
4.0 kg (baseline) vs. 59.3 ± 4.3 kg (6 months), P = 0.03). Increases versus six months 
were significant at 9 months when assessed by SF (P = 0.04) and at eighteen months 
when assessed by DXA (P = 0.03), (Fig. 2D-F). 
Overall measurements of FM showed good correlations; BIA with SF, r = 0.84, BIA with 
DXA, r = 0.89, SF with DXA, r = 0.90, P < 0.001 in all cases (Fig. 3). The changes in FM 
as measured by DXA correlated beUer with skinfold measurements than with BIA; BIA 
with SF, r = 0.46, (P < 0.001), BIA with DXA, r = 0.43, (P = 0.008), SF with DXA, r = 
0.72, (P < 0.001). 
Quality of life 
Quality of life assessment showed no significant differences between groups in 
perceived health status at baseline. There was a considerable intra-individual variation 
in several subsections of the NHP. At six months there was a significant difference in the 
section of physical mobility. This is partly due however to an increase of perceived 
problems in the placebo group (Table 2). At eighteen months the two groups were 
significantly different for this section. The increase in energy in the GH group did not 
reach significance. In the group that started with placebo there was an increase in 
energy after six months of active treatment. However this difference was not maintained 
(Table 2). On an individual basis there was substantial improvement in the patients that 
scored high at baseline. 
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TABLE 2. Nottingham Health Profile 
GH Placebo GH 
months 0 6 12 18 0 6 12 18 
Section 
Physical Mobility 3.7±1.7 2.4 ±1.5* 3.7 ±2.5 o ± 0* 9.5 ± 3.6 15.2 ± 3.0 11.0±4.4 10.7 ± 3.8 
Pain 1.11±1.0 4.0 ±2.9 3.3 ±2.1 1.4±1.4 3.1±1.5 7.5 ±4.1 14.1 ± 6.2 8.6 ± 5.4 
Sleep 7.8 ±4.2 9.2 ±4.1 11.7 ±4.9 1.4 ± 1.3 22.5 ± 9.4 11.4 ± 8.0 12.4 ± 8.5 13.8 ± 8.3 
Energy 32.2 ± 11.5 12.4 ± 6.8 9.7 ±6.8 9.7 ±4.8 32.2 ± 11.5 21.1 ±8.7 11.4±7.3# 15.5 ± 10.8 
Social Isolation 8.5 ±4.6 6.7 ±4.5 2.2±2.1 2.2 ± 2.0 6.4 ± 6.0 13.3 ± 8.7 13.3 ± 8.1 13.3 ±8.1 
Emotional Reactions 16.6 ± 6.1 6.5 ±2.S 3.0 ± 1.4 0.8 ±0.8# 21.3±11.1 17.6±8.1 8.8 ± 5.4 10.6 ±8.1 
All 11.6 ± 3.8 6.9 ±2.0 5.6 ±2.7 2.6 ± 0.8# 15.8 ± 5.6 14.3 ± 4.4 11.8 ±4.9 12.1 ± 5.5 
Results are presented as mean ± SEM. 
# P < 0.05 with',n group. 
* P < 0.05 between groups. 
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TABLE 3. Bone mineral content of lumbar spine and proximal and distal forearm 
GH Placebo GH 
months 0 6 18 0 6 18 
DXAsPINE 55.5 ±4.4 54.0 ±4.3 55.0 ±4.6 59.4 ±3.6 59.5 ± 3.5 59.8 ± 3.6 
SPA PROX 50.6 ± 3.4 49.8 ± 3.6 48.8 ± 3.6# 46.6 ± 3.9 46.7 ± 3.8 45.7 ± 3.7 
SPA OIST 53.0 ±4.2 51.9 ±4.7 50.6 ± 4.3 47.6 ± 3.8 47.5 ± 3.8 46.4 ±3.5 
Results are presented as mean ± SEM. 
#P<O.05 
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Lipid profile 
here was an improvement of the lipid profile with a temporary decrease of total and LOL-
cholesterol and a sustained increase in HOL-cholesterol. There were no between group 
differences. In the group that started with placebo there was a significant increase of 
HOL-cholesterol after six months. After starting active therapy there was also a 
significant increase versus six months (Fig. 4). 
Bone turnover and bone mineral content 
There was a significant increase in bone turnover reflected in markers of bone formation 
as well as resorption (Fig. 5). The bone formation markers alkaline phosphatase and 
osteocalcin were significantly increased versus placebo. After starting GH therapy in the 
placebo group these differences were no longer significant between the groups. 
However significance versus baseline remained. The marker of bone degradation 
(OPO) showed a significant difference between the two treatment groups at six months. 
After six months OPO cross links started to decrease, which almost reached significance 
at 18 months (P =0.051). Bone mass measurements showed a significant reduction at 
the proximal forearm after eighteen months of GH treatment (Table 3). 
DISCUSSION 
In this study we report the beneficial effects of long-term GH replacement therapy in 
patients with adult onset GHO. Effects are reported on body composition, quality of life, 
lipid metabolism, bone turnover and bone mineral mass. 
Since there were significant changes in the placebo period in body composition and 
lipids, we considered the patients groups separately during the entire eighteen month 
study period. In contrast to others we did not pool the data into one group of GH 
replacement therapy (47). 
In this study we used lower GH doses, than in previously reported studies (11.3 
j.Jg/kg.day; 0.210 IUlkg.week) which explains the fewer incidence of side effects and the 
fact that dose reduction was necessary in only three patients (including the one that 
stopped treatment) (20-22,47). 
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When studying the effects of GH therapy there were significant increases in IGF-I and 
IGFBP-3 levels. Fifteen patients had normalized IGF-I levels at eighteen months. Three 
patients had levels that could be considered too high. However, individual GH dose 
adjustment, with careful monitoring of side effects, until normal high IGF-I levels are 
reached, might prove an interesting strategy to obtain maximum biological effects of GH 
therapy in GHD patients. IGFBP-3 levels were in the normal range at baseline for the 
two groups. Mean levels were in the normal range for adults. After starting GH therapy 
there was an initial increase with a non significant tendency to decrease thereafter. 
Since this decrease is not found in the IGF-I levels this further corroborates our earlier 
observation that IGFBP-3 levels are not helpful in defining the optimal GH dose (31). 
Glucose metabolism was only slightly affected in our patients. Although a Significant 
increase in HbA,C levels implicates that mean glucose levels must have increased, no 
support for this was found in extensive studies of OGTI data on glucose and insulin. 
The fact that HbA,C levels decrease, while mean GH dose was only slightly reduced, 
suggests that there is a mild, transient glucose intolerance. Evaluation with euglycemic 
clamp studies might further elucidate this point. 
Overall correlations between the three methods of body composition assessment (BIA, 
SF, DXA) are good. The reduction of FM, however, was best demonstrated by SF and 
DXA, and not by BIA. 
The validation of the BIA method under different circumstances (hydration status), in 
different patient groups (obese, growth hormone deficient, elderly), using different body 
impedance analyzers, differences in electrode placement and using different prediction 
formulas is still a matter of debate (48-53). Also the validity of the basic equation is 
discussed in that it cannot detect changes in body composition unless they are 
considerable (54). The BIA method assesses TBW or FFM depending on the regression 
equation used. From TBW, FFM and FM can be calculated with the formula's FFM = 
TBW/O.73 and FM = BW - FFM. This formula uses the Pace constant for the hydration 
of the lean body of 0.732 (55). In other words water constitutes 73.2% of FFM in adult 
man. However, this assumption is based upon animal studies, in guinea pigs and 
several other small animals and has certainly not been validated in humans (55,56). 
From an extensive review of the literature, it has been concluded that in normal humans 
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the water content of the FFM ranges from 70 to 78%, with a mean value of 73% (56). 
This, however, requires a normal hydration status and the absence of electrolyte 
disturbances, which do not change during GH therapy. This is obviously not the case in 
GHD patients (3,31). Therefore the BIA technique cannot be used in longitudinal studies 
on GH therapy to assess changes in FM. 
Since SF represents measurements of FM and not FFM it might be more accurate in 
detecting changes in FM. The only adjustments that have to be made are for age and 
sex. The DXA method is well validated and measures fat directly (37,57,58). The 
measurement of fat by DXA is derived from the ratio of the mass attenuation coefficients 
for the two energies of a constant x-ray source of 40 and 70 keV (R). This R-value has a 
linear relation to fat percentage. The %fat times the measured soft tissue mass gives the 
fat mass; the remainder is the lean tissue mass. This also implicates that DXA does not 
distinguish between intra- and extracellular water. The DXA method therefore is different 
from the other methods of body composition assessment, because it measures body 
composition independently from age, water, or any other factor of the FFM. 
In the group as a whole, there were only minor changes in perceived health status. In 
the NHP, patients score higher when they perceive more problems. Some patients, do 
not score high at baseline, maybe because they have become adjusted to their impaired 
capacities. On an individual basis there was substantial improvement in the patients that 
score high at baseline, especially in the section energy. The intra-individual variation 
was considerable. This means that larger patient groups are needed to prove a 
beneficial effect of GH therapy on quality of life. 
The rise of HDL-cholesterol in the placebo group is unexplained. Changes in lipid profile 
during GH treatment were favorable and persisted throughout the study period as 
elevated HDL-cholesterollevel. Since HDL-cholesterol is an important independent risk 
factor in cardiovascular disease, this increase will probably improve long-term prognosis 
in GHD patients. 
The increases in bone turnover parameters were sustained throughout the study period. 
Interestingly the markers of bone resorption (deoxypyridinoline) start to decline, while 
the markers of bone formation are still rising (osteocalcin) or maintain elevated (alkaline 
phosphatase). This could implicate uncoupling of bone formation and resorption, in 
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favor of bone formation. In this study with 12 months and 18 months of GH therapy only 
minor changes in BMC were found. A longer observation period turned out to be 
necessary to demonstrate long-term positive effecls on bone mineral mass in GHD adult 
patients (59). 
We conclude that long-term GH replacement therapy in patients with adult onset GHD 
results in favorable effects on body composition, HDL-cholesterol levels and bone 
turnover. Side effecls of long-term GH replacement therapy are fewer when smaller 
doses are used. The changes in body composition are easily and accurately detected 
by skinfold anthropometry and not by bioelectrical impedance analysis. As skinfold 
anthropometry is an easy, patient-friendly and cheap procedure, this method should be 
used in the evaluation of the efficacy of GH replacement therapy in GHDA patients. 
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7 Summary, synthesis and future 
Summary 
After the development of GH biosynthesis by recombinant DNA techniques the number 
of studies with human GH has greatly increased. The prior restrictions of its use due to 
scarcity were lifted, and studies of GH action and therapy other than in childhood growth 
hormone deficiency (GHD) were initiated (chapter 1.1 & 1.2). 
The human body consists for a substantial part of proteins mainly in the form of muscle. 
In GHD patients muscle mass is decreased. Also, general diseases in man greatly affect 
body protein turnover by causing a negative nitrogen (protein) balance. Since GH acts 
as an anabolic hormone and induces a positive nitrogen balance, nitrogen metabolism 
is important when studying the effects of GH therapy (chapter 1.3). 
The assessment of body composition can be achieved by several principally different 
techniques. These methods are influenced by several parameters of disease and 
cannot be applied routinely in all patients without taking the disease characteristics into 
account (chapter 1.4). 
In the late 1980s and early 1990s the results of the first long-term studies on GH 
replacement therapy in adults were reported and the features of the GHD syndrome in 
adulthood were described. These include among others an increase in body fat and a 
decrease in lean body mass, an impaired physical performance, a decrease of bone 
mineral mass, disorders in lipid metabolism, the development of premature 
atherosclerosis, and a decreased quality of life (chapter 1.5). 
The unlimited availability of hGH resulted in a considerable expansion of studies into 
potential new indications for GH treatment other than replacement therapy (chapter 
1.6). 
Long-term safety reports concerning GH therapy are not available in adults. Experience, 
however, is increasing since large numbers of GHD adult patients take part in large 
multi-center trials on GH replacement therapy, mainly in Europe. No deleterious side-
effects of long-term GH therapy have been observed so far. They are also not expected 
to occur, as the GH dose administered is within the physiological "replacement" range 
(chapter 1.7). 
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In this thesis several aspects of the GHD syndrome in adulthood, as well as of GH 
replacement therapy and GH therapy in adults were studied. 
The potential differences in the signs and symptoms of GHD in adullhood were studied 
in 173 patients. The childhood onset (CO) GHD patients (n=74) were younger and 
smaller than the adult onset (AO) patients (n=99). CO as well as AO patients tended to 
be obese, with a preference of increased adipose tissue mass around the waist in AO 
patients. Lean body mass was especially lowered in CO GHD patients. Osteocalcin 
levels were elevated in most CO patients, while lipid abnormalities (increased 
cholesterol and lowered HDL-cholesterol levels) especially occurred in AO GHD 
individuals. Quality of life, as evaluated with the Nottingham Health Profile questionnaire 
showed abnormal dimension scores in all six subscales for both CO and AO GHD 
patients, but the degree of distress for physical mobility and energy levels was 
significantly higher in AO individuals. These results demonstrate considerable 
differences in the clinical and biochemical presentation of the adult GHD syndrome. 
Adult patients with idiopathic CO GHD show somatic underdevelopment similar to 
pituitary dwarfism: they remain too small, have generalized obesity and a lowered 
muscle mass, elevated osteocalcin levels, marginal abnormalities in their lipid 
metabolism and are relatively content with their life. It seems as if they have not fully 
completed development yet. Somatic development is complete in AO GHD patients, 
however, who previously have experienced the full advantage of health and physical 
maturation. Most of them are obese, with a central abdominal localization, the majority of 
them have lowered HDL-cholesterol levels indicating the risk of premature 
atherosclerosis. Subjectively, they experience a greater loss of their quality of life 
(chapter 2). 
Thereafter the potent anabolic effects of GH on nitrogen metabolism were investigated 
in four GHDA patients in a metabolic ward study. Measurement of IGFBP-3 levels 
seems to offer no additional information as to defining the optimal GH replacement 
dose. Sodium retention in the first days after the initiation of GH replacement therapy is 
considerable and largely influences the assessment of body composition by BIA, 
rendering this technique in fact unsuitable in evaluating the initial changes in body 
composition during GH replacement therapy. BIA does not measure body composition 
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but gives information reHecting the extracellular volume and its electrical conductivity, 
expressed as resistance measured between two ipsilateral extremities. This value is 
abnormal in untreated GHD adults and normalizes within a few days after the initiation 
of GH replacement therapy (chapter 3). 
GH has both direct and indirect effects on bone turnover and bone mineral mass. GHD 
patients have a lowered bone mineral content (BMC). In a previous study we obseNed, 
an initial (temporary) further decrease of BMC during the first six months of GH 
replacement therapy. This can be explained by an increase in bone turnover and 
remodeling. In the present study, the effects of the combined treatment of GH 
replacement therapy with an inhibitor of bone resorption, pamidronate, was investigated 
in six GHD adult patients. It was hypothesized that the initial decrease as found with GH 
therapy only could be prevented by the bisphosphonate. After six months of combined 
treatment, indeed an increase in BMC was obseNed while bone turnover remained 
activated. This suggests a net positive effect on the coupling of bone resorption and 
bone formation and might favor initial adjuvant pamidronate to GH replacement in GHD 
patients with a lowered bone mineral mass. Furthermore the effects of the addition of 
pamidronate to GH replacement on renal phosphate handling were studied. GH (or IGF-
I) induces phosphate retention independently from PTH and only partially antagonizes 
the phosphaturic effect of PTH (chapter 4). 
Since inhibition of bone resorption by pamidronate causes an increase in BMC, while 
GH activates bone turnover, it was hypothesized that combined treatment with both 
compounds might also be of benefit in postmenopausal osteoporosis. Twenty-one 
osteoporotic elderly women were randomly assigned to two groups and were studied in 
a placebo-controlled manner with GH vs. placebo for six months, while all patients 
received pamidronate for twelve months. Bone mass increased in the placebo group 
(pamidronate only), while bone mass did not change in the patients treated with GH and 
pamidronate. Bone turnover decreased below baseline in the placebo group, while it did 
not change in the GH group. It can be concluded that the combined treatment of GH and 
pamidronate offers no new approach to the treatment of postmenopausal osteoporosis. 
However, six months might in retrospect have been a too short treatment period and 
other treatment schedules might prove more beneficial (chapter 5). 
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Finally the effects of long-term GH replacement in patients with adult onset GHD were 
studied. Twenty patients entered an eighteen month GH replacement study, of which 
the first six months were placebo-controlled. Beneficial effects were found on body 
composition and lipid profile. Bone turnover increased but did not result in an increment 
of bone mass at twelve and eighteen months, respectively. Side effects were mild and in 
most causes transient or reversible by dose reduction. There was a mild deterioration of 
glucose tolerance which had a tendency to improve toward the end of the study. 
Interestingly it was found that skinfold anthropometry was a reliable indicator of body 
composition change, this in contrast with BIA. This further corroborates our findings in 
chapter 3. Since skinfold anthropometry is an easy, patient-friendly and cheap 
procedure, it is suggested that this method should be used in the evaluation of the 
efficacy of GH replacement therapy in GHDA patients (chapter 6). 
Synthesis and Future 
GH is a potent anabolic hormone. GH replacement in adults with GHD is beneficial to 
the health status of these patients. GH causes a positive nitrogen, potassium and 
phosphate balance and increases lean body mass, meanwhile decreasing fat mass. 
Also the effects on sodium retention and extracellular volume are substantial. GH has 
stimulatory effects on bone turnover and when combined with an inhibitor of bone 
resorption it causes an increase of bone mass, occurring already during the first six 
months of therapy. No potential role for GH was found in the treatrnent of 
postmenopausal osteoporosis. Long-term GH replacement in GHD adults leads to 
significant favorable changes in body composition and in the lipid profile, thereby 
diminishing risk factors for the development of premature atherosclerosis. In the 
evaluation of changes of body cornposition during GH replacernent, assessment by BIA 
is not suitable and skinfold anthropometry is to be preferred. 
The registration by the authorities of human GH for treatment in GHDA patients is only a 
matter of time. However, this does not necessarily implicate that all GHD patients will 
benefit from, or should receive GH replacement therapy. 
By definition all patients which suffer from the GHD syndrome are GHD, as determined 
by an inadequate response to GH stimulation tests. The opposite, however, that all 
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GHD adult patients suffer from the GHD syndrome remains uncertain. Also, there is a 
possibility of a third group of patients with signs and symptoms of the GHD syndrome, 
with a normal GH response to a stimulation test, but lowered IGF-I levels, reflecting 
impaired 24-hours GH secretion. More studies should be done on these aspects. The 
considerable differences in the clinical and biochemical symptomatology between adult 
GHD of childhood and adult onset underline that especially in the AO GHD who had 
previously led a normal life, individual GH replacement therapy improves the subjective 
psychological distress and increases HDL-cholesterol levels, thereby preventing 
premature atherosclerosis. The group of CO GHD adults demonstrate a number of 
features of pituitary dwarfism. Several signs and symptoms, as well as biochemical 
parameters, suggest that most individuals have not yet reached full somatic and 
psychological development, despite previous GH therapy in order to reach their adult 
height. Therefore it is anticipated that our obseNations support that, at the end of 
puberty, GH therapy in this category of GHD individuals should be continued into 
adulthood, without interruption in order to induce full maturation. 
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8 Samenvatting voor de niet-medicus 
In het begin van deze eeuw werd aangetoond, dat groei wordt gereguleerd door een 
stof uit de hypofyse (hersenaanhangsel), die momenteel groeihormoon (GH) wordt 
genoemd. GH werd gezuiverd uit de hersenen van overledenen en was daarom 
schaars. Dit GH werd vooral gereserveerd voor kinderen met achtergebleven 
lengtegroei tengevolge van groeihormoondeficientie (GHD) . Sinds de ontwikkeling 
van kunstmatig menselijk groeihormoon (GH) met behulp van recombinant DNA 
technieken is het aantal studies met GH enorm toegenomen. De eerder opgelegde 
beperkingen tengevolge van de schaarste werden opgeheven en met onderzoek 
naar de werking van GH en GH behandeling voor andere indicaties dan GHD bij 
kinderen werd een begin gemaakt. (hoofdstuk 1.1 & 1.2). 
Het menselijk lichaam be staat voor een groot deel uit eiwitten, voornamelijk in de 
vorm van spierweefsel. Bij patienten met GHD is er sprake van een afname van de 
spiermassa. GH heef! een belangrijke taak bij het handhaven van de eiwit (stikstof) 
balans. Veel ziekten be'invloeden de eiwitstofwisseling en veroorzaken een 
negatieve eiwit balans met allerlei negatieve effecten op vele lichaamsfuncties. 
Daar GH een anabool (opbouwend) effect heef! en een positieve eiwitbalans kan 
bewerkstelligen, is deze balans van belang, wanneer de effecten van GH behan-
de ling worden bestudeerd (hoofdstuk 1.3). 
De lichaamssamenstelling (waaronder de spiermassa) kan op meerdere manieren 
worden gemeten. Bij deze meetmethoden worden verschillende technieken gebruikt. 
Daar de methoden door vele factoren (o.a. ziekte) worden be'invloed kunnen ze niet 
zonder meer willekeurig worden toegepast (hoofdstuk 1.4). 
Aan het einde van de jaren tachtig en in het begin van de jaren negentig, werden de 
eerste resultaten van langdurige GH behandeling bij GHD volwassenen beschre-
ven. Tevens werden de belangrijkste kenmerken van GHD bij volwassenen gede-
finieerd en werd het beeld van het groeihormoondeficientiesyndroom bij volwas-
senen duidelijk. Dit omvat o.a. een toe name van lichaamsvet en een afname van 
spiermassa, een verminderd inspanningsvermogen, een vermindering van 
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bot massa, verstoring van de vet (cholesterol) stofwisseling, vroegtijdige ader-
verkalking en een verminderde kwaliteit van leven (hoofdstuk 1.5). 
De welhaast onbeperkte beschikbaarheid van GH, he eft ook onderzoek naar nieuwe 
toepassingsmogelijkheden van GH mogelijk gemaakt. Dit betreft 0.8. kleine kinderen 
zonder GHD, patienten met overgewicht, ouderen, patienten met ernstige ziekten 
zoals bv. na brandwonden, ernstige bloedvergiftiging, ontstekingen, na ongevallen 
of grote operaties, patienten met heupfracturen, patienten die met bijnierschors-
hormoon (bv. prednison) worden behandeld, patienten met kanker, patienten met 
AIDS, vrouwen met botontkalking na de menopauze (hoofdstuk 1.6). 
Er zijn nog geen resultaten bekend van onderzoek naar de veiligheid van GH 
behandeling op de lange termijn. De ervaring op dit gebied neemt echter snel toe, 
door de grote aantallen patienten, die deelnemen aan onderzoek naar de effecten 
GH behandeling op de volwassen leeftijd. Er zijn tot nog toe geen nadelige effecten 
van GH behandeling aangetoond. De belangrijkste klachten, die soms kort na de 
start van de behandeling optreden zijn spierpijn en "vocht vasthouden". Deze 
klachten verdwijnen spontaan of na geringe veri aging van de hoeveelheid 
toegediend GH. Ook op theoretische gronden is het niet te verwachten, dat er 
belangrijke bijwerkingen zullen optreden, daar het gaat om "het vervangen van wat 
op onnatuurlijke wijze ontbreekt". 
In dit proefschrift worden resultaten van onderzoek naar het GHD syndroom op de 
volwassen leeftijd, GH behandeling bij GHD volwassenen en GH behandeling bij 
vroegtijdige botontkalking bij vrouwen beschreven. 
De mogelijke verschillen in GHD op de volwassen leeftijd werden bestudeerd in 173 
patienten. Patienten die reeds als kind GHD waren (childhood onset; CO) waren 
jonger en kleiner dan de patienten die op volwassen leeftijd GHD werden (adult 
onset; AO). Zowel CO als AO patienten toonden een neiging tot overgewicht, met 
een voorkeur voor vetophoping rond de buik bij AO patienten. In het bijzonder bij de 
CO GHD patienten was er een vermindering van het vetvrije gedeelte van het 
lichaam, hetgeen voor een groot deel uit spier bestaat. Afwijkingen in de choles-
terolspiegels komen vooral bij AO GHD voor. De kwaliteit van leven, zoals deze 
werd gemeten met uitgebreide vragenlijsten, toonden afwijkingen op aile gemeten 
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gebieden voor be ide patient groepen, maar de beperkingen in lichaams-
beweegbaarheid en energie waren beduidend ernstiger in AO GHD. Deze 
resultaten tonen belangrijke verschillen tussen CO en AO GHD. Volwassen 
patienten met CO GHD tonen verschijnselen van lichamelijke onderontwikkeling; ze 
blijven te klein, ze hebben gegeneraliseerd overgewicht en een verminderde spier-
massa, ze hebben geringe cholesterol afwijkingen en zijn relatief tevreden met hun 
leven. In AO GHD is de lichamelijke ontwikkeling voltooid. Meeste patienten hebben 
overgewicht, welk meer rond de buik is gelokaliseerd. De meerderheid heeft 
afwijkende cholesterolwaarden met een verhoogd risico op vroegtijdige 
aderverkalking. Deze patienten ervaren een groter verlies in kwaliteit van leven 
(hoofdstuk 2). 
Daarna worden de sterke anabole effecten van GH op de stikstofstofwisseling 
beschreven, zoals deze werden bestudeerd in een balans studie bij vier GHD 
patiElnten. V~~r dit onderzoek werden de patiElnten 24 dagen opgenomen. 
Gedurende 15 dagen werden de patienten met GH behandeld. Tijdens deze 
opname nuttigden zij elke dag dezelfde maaltijd. Een van deze maaltijden werd 
volledig gemengd en onderzocht op de samenstelling. Aile urine en ontiasting werd 
verzameld. Door het verschil tussen in (maaltijd) en uit (urine en ontiasting) te 
meten kon het effect van GH op o.a. de stikstofstofwisseling en de zout en water 
huishouding worden bestudeerd. Er blijkt een zeer snel effect te zijn op het 
vasthouden van water en zout als gevolg van GH behandeling. Ook het positieve 
effect op de stikstofstofwisseling is al na twee dagen aantoonbaar. Uit dit onderzoek 
werd tevens duidelijk dat de lichaamssamenstelling meting die gebaseerd is op de 
elektrische weerstand van het lichaam ongeschikt is bij GHD patienten die met GH 
worden behandeld. De meting geeft meer informatie over de hoeveelheid 
lichaamswater dan over de hoeveelheid lichaamsvet (hoofdstuk 3). 
GH heeft een positieve invloed op de botstofwisseling en de botmassa. GHD 
patienten hebben een verlaagde botmassa. Een verlaagde botmassa vormt een 
verhoogd risico op wervelinzakkingen en botbreuken van de heup. In een eerdere 
studie werd door ons aangetoond, dat in het begin van GH behandeling de 
botmassa iets daalt. Dit lijkt te kunnen worden verklaard door een toename van de 
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botombouwactiviteit. Anderen toonden reeds aan dat een voorgezette G H behan-
deling de botmassa doet stijgen, Er bestaan tevens medicijnen die de botafbraak 
rem men, In een onderzoek dat werd uitgevoerd bij zes GHD patienten werd deze 
remmer van de botafbraak gecombineerd met de stimulator van de botstofwisseling 
GH, De veronderstelling was, dat het hierdoor mogelijk zou kunnen zijn, de 
botmassa direct na aanvang van GH therapie te laten stijgen, Dit bleek inderdaad 
het geval na zes maanden behandeling, Dit zou kunnen betekenen dat een 
gecombineerde behandeling het evenwicht van botafbraak en botaanmaak op een 
gunstige manier beinvloed (hoofdstuk 4), 
Omdat het rem men van de botafbraak op zich al een toename van de bot mass a 
bewerkstelligt en GH de botombouw stimuleert, zou een gecombineerde 
behandeling ook van betekenis kunnen zijn bij vrouwen met een verlaagde 
botmassa na de overgang (postmenopauzale osteoporase), Een en twintig vrauwen 
werden bestudeerd, gedurende een jaar. Zij kregen allen een remmer van de 
botafbraak, In het eerste half jaar kreeg de helf! van de vrouWen GH behandeling, 
de andere helf! een niet werkzame injectie vloeistof (placebo), Zowel de patient als 
de onderzoeker waren pas na afloop van de behandeling op de hoogte van de 
ingestelde behandeling (GH of placebo), In de groep met placebo behandeling was 
er een stijging van de botmassa (zoals te verwachten) met een vermindering van de 
botombouw, In de graep met GH behandeling bleef de botmassa echter gelijk met 
een gelijkgebleven botombouw, Er was dus geen positief effect van GH, Achteraf 
kan mogelijk worden verondersteld, dat de behandeling te kort heef! geduurd of dat 
het behandelingschema anders had moeten zijn (hoofdstuk 5), 
Tenslotte worden de resultaten beschreven van langdurige GH behandeling bij 
twintig AO GHD patienten, Er werden gunstige effecten gevonden op lichaams-
samenstelling en vetstofwisseling, De botombouw nam toe maar resulteerde niet in 
een toename van de botmassa bij aile patienten, De bijwerkingen waren gering en 
van voorbijgaande aard, Er was een geringe stoornis in de suikerstofwisseling, die 
tegen het einde van de studieperiode weer herstelde, Een interessante bevinding 
was bovendien, dat lichaamssamenstelling meting met behulp van het meten van 
onderhuidse vetplooien betrouwbaarder resultaten opleverde dan meting via de 
172 
Klinische aspecten van groeihonnoonbehandeling bij volwassenen 
elektrische weerstand van het lichaam. Vetplooimeting is goedkoop en simpel en 
kan daarom goed gebruikt worden om de effectiviteit van GH behandeling bij GHD 
patienten te meten (hoofdstuk 6). 
GH en de toekomst 
GH is een krachtig anabool hormoon. GH behandeling bij volwassenen met GHD is 
gunstig voor de gezondheid van deze patienten. GH veroorzaakt een positieve 
stikstof, kalium en fosfaatbalans en doet de spiermassa toenemen terwijl de 
vetmassa afneemt. Ook de effecten op water- en zouthuishouding zijn aanzienlijk. 
GH heelt een stimulerend effect op de botombouw en, indien gecombineerd met een 
remmer van de botafbraak, doet de botmassa toenemen bij GHD patient en. Er 
werd geen rol aangetoond voor GH therapie in postmenopauzale osteoporose. 
Lange termijn GH behandeling van GHD patienten leidt tot positieve effecten op 
lichaamssamenstelling, cholesterol en daarmee tot een gunstiger vooruitzicht met 
betrekking tot vroegtijdige aderverkallking. De veranderingen in lichaamssamen-
stelling kunnen zeer goed worden gemeten met een simpele huidplooimeter. 
Inmiddels werd menselijk GH geregistreerd voor de behandeling bij GHD volwas-
senen. Dit betekent echter niet zonder meer dat aile patienten voordeel zullen 
ondervinden van GH therapie en ook niet dat al deze patienten met GH zouden 
moeten worden behandeld. Per definitie zijn aile patienten die aan het GHD 
syndroom lijden GHD. Oat wil echter nog niet zeggen dat aile GHD patienten lijden 
aan het GHD syndroom. Daarnaast is er mogelijk een derde groep patienten met 
kenmerken en klachten van het GHD syndroom zonder dat ze GHD zijn. 
De aanzienlijke verschillen tussen CO en AO GHD zoals wij deze hebben 
waargenomen, ondersteunen de inschatting dat in de toekomst, aan het einde van 
de puberteit, GH behandeling dient te worden voortgezet om volledige ontwikkeling 
mogelijk te maken en de complicaties van GHD te doen voorkomen. Daarnaast 
be staat er inmiddels voldoende aanleiding om bij patienten die op volwassen leeftijd 
GHD zijn geworden GH substitutie te overwegen. 
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